Zahid Hussain Siddik, Ph.D.

Department of Experimental Therapeutics, Division of Cancer Medicine

Present Title & Affiliation

Primary Appointment

Professor of Medicine (Pharmacology), Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX

Dual/Joint/Adjunct Appointment

Professor of Medicine (Pharmacology), Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX

Member, Graduate School of Biomedical Sciences (GSBS), Houston, TX

Research Interests

Presence of wild-type p53 is prevalent in many refractory cancers. My current interests are focused on understanding how drug resistance is induced when wild-type p53 is present and how such a mechanism can be circumvented through drug design. More specifically, we are focused on the dysfunctionality of the p53/p21 pathway and how it impacts apoptosis through loss of checkpoint response.

Education & Training

Degree-Granting Education

1975	St. Mary's Hospital Medical School, University of London, London, US, Biochemistry, Ph.D
1972	University of Liverpool, Liverpool, GB, Biochemistry, BS

Postgraduate Training

1976-1980	Fogarty Postdoctoral Fellow, National Cancer Institute, National Institutes of Health, Bethesda, Maryland
null-1984	Postgraduate Fellow, Institute of Cancer Research, Sutton, Surrey

Experience & Service

Faculty Academic Appointments

Adjunct Professor, Pharmacology, University of Houston, Houston, TX, 1988 - 1999

Associate Professor of Medicine (Pharmacology) and Associate Pharmacologist, Department of Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 1987 - 1995

Staff Scientist and Leader, Dept. of Biochemical Pharmacology, The Institute of Cancer Research, University of London, Belmont, Sutton SM2 5PX, Surrey, 1984 - 1987

Research Scientist, Dept. of Biochemical Pharmacology, The Institute of Cancer Research, University of London, Belmont, Sutton SM2 5PX, Surrey, 1980 - 1984

Administrative Appointments/Responsibilities

Chairman (ad interim), Department of Experimental Therapeutics, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 1999 - 2003

Other Professional Positions

Consultantships, OncoTEX Inc, New York, NY, 2020 - Present

Consultantships, Valent Technologies LLC, Menlo,CA, 2017 - 2019

Director, Mentoring Program, Department of Experimental Therapeutics, Houston, TX, 2013 - Present

Consultantships, King Fahd University of Petroleum & Minerals, Saudi Arabia, 2010 - 2016

Consultantships, XenoPort, Inc, San Jose, CA, 2005 - 2016

Consultantships, Alkermes, Inc, Cambridge, MA, 1995 - 1998

Drug Development Program, Institute of Cancer Research, Department of Biochemical Pharmacology, Sutton, Surrey, England, 1987 - 1989

Extramural Institutional Committee Activities

Member, Institutional Faculty Senate, The University of Texas MD Anderson Cancer Center, 2021 - Present

Ex Officio Member, Faculty Senate Election Committee, The University of Texas MD Anderson Cancer Center, 2020

Member, Institutional Decision Maker Conflict of Interest Committee, The University of Texas MD Anderson Cancer Center, 2019 - Present

Member, MD Anderson Graduate Education Committee, The University of Texas MD Anderson Cancer Center, 2019 - Present

Member, Search Committee, Chair of the Department of Comparative Medicine, The University of Texas MD Anderson Cancer Center, 2019 - 2020

Member, Faculty Senate Institutional Policy Review Committee, The University of Texas MD Anderson Cancer Center, 2019 - 2020

Member, Institutional Bridge Funding Committee, The University of Texas MD Anderson Cancer Center, 2018 - Present

Member, Institutional Historical Resources Center (HRC) Steering Committee, The University of Texas MD Anderson Cancer Center, 2018 - 2021

Member, PRS Compensation Committee, The University of Texas MD Anderson Cancer Center, 2018 - 2019

Member, Faculty Senate Research Endowment Committee, The University of Texas MD Anderson Cancer Center, 2017 - 2020

Member, Institutional Executive Committee of the Faculty Senate, The University of Texas MD Anderson Cancer Center, 2016 - 2020

Selection Committee, Alfred G. Knudson, Jr. Outstanding Dissertation Award, The University of Texas MD Anderson Cancer Center, 2015 - 2016

Member, Institutional Faculty Senate Byelaws Committee, The University of Texas MD Anderson Cancer Center, 2014 - Present

Chair, Institutional Faculty Senate Byelaws Committee, The University of Texas MD Anderson Cancer Center, 2014 - 2020

Chair, Faculty Achievement Awards Committee, The University of Texas MD Anderson Cancer Center, 2014 - 2018

Director, Mentoring Program, Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, 2013 - Present

Member, Faculty Achievement Awards Committee, The University of Texas MD Anderson Cancer Center, 2013 - 2019

Selection Committee, Alfred G. Knudson, Jr. Outstanding Dissertation Award, The University of Texas MD Anderson Cancer Center, 2013 - 2014

Member, Institutional Faculty Senate, The University of Texas MD Anderson Cancer Center, 2012 - 2020

Member, Institutional Faculty Senate Compensation Committee, The University of Texas MD Anderson Cancer Center, 2010 - 2011

Chairman, Benvenuto Memorial Award Lecture Committee, The University of Texas MD Anderson Cancer Center, 2007 - Present

Chairman, Seminar Organization Committee Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, 2007 - 2013

Member, Institutional Faculty Senate, The University of Texas MD Anderson Cancer Center, 2005 - 2011

Member, Seminar Organization Committee, Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, 2004 - Present

Member, Faculty Health Committee, The University of Texas MD Anderson Cancer Center, 2004 - 2007

Chairman, Faculty Compensation Committee, The University of Texas MD Anderson Cancer Center, 2004 - 2006

Member, Faculty Compensation Committee, The University of Texas MD Anderson Cancer Center, 2004 - 2006

Member, Institutional Communication Advisory Committee, The University of Texas MD Anderson Cancer Center, 2003 - 2011

Member, Technology Champions Project Team, The University of Texas MD Anderson Cancer Center, 2003 - 2007

Member, Pharmaceutical Development Center Users Committee, The University of Texas MD Anderson Cancer Center, 2002 - 2003

Member, Chaplaincy Advisory Committee, The University of Texas MD Anderson Cancer Center, 2002

Chairman, Faculty Compensation Sub-Committee, The University of Texas MD Anderson Cancer Center, 2001 - 2004

Member, Faculty Compensation Sub-Committee, The University of Texas MD Anderson Cancer Center, 2001 - 2004

Member, Executive Committee of the Science Faculty, The University of Texas MD Anderson Cancer Center, 2001 - 2003

Chairman, Term Appointment Committee for Non-Tenured Faculty, The University of Texas MD Anderson Cancer Center, 2001

Member, Diversity Council, The University of Texas MD Anderson Cancer Center, 2000 - 2004

Reviewer, Cancer Therapeutics Discovery Program Grant, The University of Texas MD Anderson Cancer Center, 2000 - 2003

Member, Intellectual Property Oversight Committee, The University of Texas MD Anderson Cancer Center, 2000 - 2003

Member, GSBS Academic Standards Committee, The University of Texas MD Anderson Cancer Center, 2000 - 2003

Member, Oversight Committee: Cancer Therapeutics Discovery Program and Pharmaceutical Development Center, The University of Texas MD Anderson Cancer Center, 2000 - 2002

Member, Term Appointment Committee for Non-Tenured Faculty, The University of Texas MD Anderson Cancer Center, 2000 - 2002

Member, Leadership Steering Committee, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, 2000 - 2001

Member, OPR Research Integrity ad hoc Committee, The University of Texas MD Anderson Cancer Center, 2000

Member, Search Committee, Head of the Division of Diagnostic Imaging, The University of Texas MD Anderson Cancer Center, 2000

Chairman, Institutional Biosafety Committee, The University of Texas MD Anderson Cancer Center, 1999 - Present

Member, OPR Scientific Advisory Committee, The University of Texas MD Anderson Cancer Center, 1999 - 2009

Member, Research Funding Oversight Committee, The University of Texas MD Anderson Cancer Center, 1999 - 2009

Member, Odyssey Postdoctoral Program Review Committee, The University of Texas MD Anderson Cancer Center, 1999 - 2006

Member, Faculty Advisory Committee for the New Institutional Grants Program, The University of Texas MD Anderson Cancer Center, 1999 - 2005

Member, Division of Cancer Medicine Executive Council, The University of Texas MD Anderson Cancer Center, 1999 - 2003

Member, Research Council Subcommittee: New CCSG Shared Resource Requests, The University of Texas MD Anderson Cancer Center, 1999 - 2003

Member, GSBS Program in Toxicology, The University of Texas MD Anderson Cancer Center, 1998 - 2008

Chairman, Faculty Compensation Advisory Committee, The University of Texas MD Anderson Cancer Center, 1998 - 2004

Member, Faculty Compensation Advisory Committee, The University of Texas MD Anderson Cancer Center, 1998 - 2004

Member, Steering Committee on Cancer and Minorities, The University of Texas MD Anderson Cancer Center, 1998 - 2003

Special Reviewer, Biomedical Research Support Grant Committee, The University of Texas MD Anderson Cancer Center, 1998 - 2003

Member, Faculty Senate Executive Committee, The University of Texas MD Anderson Cancer Center, 1998 - 1999

Member, Faculty Senate Research Issues Committee, The University of Texas MD Anderson Cancer Center, 1998 - 1999

Chairman, Faculty Senate Salary Review Committee, The University of Texas MD Anderson Cancer Center, 1998 - 1999

Member, Institutional Biosafety Committee, The University of Texas MD Anderson Cancer Center, 1997 - Present

Member, Executive Council, Minority Faculty and Administrators Committee, The University of Texas MD Anderson Cancer Center, 1997 - 1999

Chairman, Chemical and Biochemical Hazard Sub-Committee, The University of Texas MD Anderson Cancer Center, 1997 - 1999

Member, Faculty Classification Committee/Promotion and Tenure Committee, The University of Texas MD Anderson Cancer Center, 1997 - 1999

Member, Faculty Senate Salary Review Committee, The University of Texas MD Anderson Cancer Center, 1997 - 1999

Chairman, Minority Faculty and Administrators Committee, The University of Texas MD Anderson Cancer Center, 1997 - 1998

Member, Faculty Achievement Awards Parent Committee, The University of Texas MD Anderson Cancer Center, 1997

Member, Faculty Achievement Awards Parent Committee, The University of Texas MD Anderson Cancer Center, 1996

Member, Minority Faculty and Administrators Committee, The University of Texas MD Anderson Cancer Center, 1994 - 1998

Chairman, Faculty Senate Search Policy Committee, The University of Texas MD Anderson Cancer Center, 1994 - 1996

Member, Faculty Senate Search Policy Committee, The University of Texas MD Anderson Cancer Center, 1994 - 1996

Member, Women and Minority Faculty and Administrator Visibility Committee, The University of Texas MD Anderson Cancer Center, 1994 - 1995

Member, Medical Oncology Fellowship Advisory Committee, The University of Texas MD Anderson Cancer Center, 1994

Member, Institutional Faculty Senate, The University of Texas MD Anderson Cancer Center, 1993 - 1999

Member, Faculty Senate Tenure & Promotions Committee, The University of Texas MD Anderson Cancer Center, 1993 - 1999

Chairman, Seminar Organization Committee, Department of Clinical Investigation, The University of Texas MD Anderson Cancer Center, 1993 - 1994

Member, Seminar Organization Committee, Department of Clinical Investigation, The University of Texas MD Anderson Cancer Center, 1993 - 1994

Member, Admissions Committee for the GSBS Program in Toxicology, The University of Texas MD Anderson Cancer Center, 1992 - 1994

Ad Hoc Reviewer, Institutional Animal Care and Use Committee, The University of Texas MD Anderson Cancer Center, 1991 - 2004

Member, Institutional Leadership Committee, The University of Texas MD Anderson Cancer Center, 1990 - 1991

Member, Laboratory Animal Resource Management Group, The University of Texas MD Anderson Cancer Center, 1989 - 1991

Chairman, Institutional Animal Care and Use Committee, The University of Texas MD Anderson Cancer Center, 1989 - 1991

Member, Institutional Animal Care and Use Committee, The University of Texas MD Anderson Cancer Center, 1988 - 1991

Editorial Activities

Member of Editorial Review Board, Journal of Rashid Latif Medical College, 2013 - Present

Guest Editor, International Journal of Hyperthermia, 1997

Member of Editorial Review Board, International Journal of Oncology: Oncology Reports, 1996 - 2000

Honors & Awards

2018	Gerald P. Bodey Award for Excellence in Teaching, Division of Cancer Medicine
2016	MD Anderson Provost's Distinguished Faculty Mentor Awards
2015	Experimental Therapeutics Academic Program Mentoring Award
1991	Queen's Award for Technological Achievement: Development of Carboplatin, Government of United Kingdom
1984	Faculty Life Tenure, The Institute of Cancer Research
1983	Outstanding Research Award, 10th International Symposium on the Biological Characterization of Human Tumours: Cancer Chemotherapy and Selective Drug Development, Brighton, England
1976	Fogarty Fellowship Recipient, NIH
1972	Outstanding Undergraduate Award, Liverpool University

Professional Memberships

Cancer Molecular Therapeutics Research Association (CMTRA)

2014 - Present

American Society of Clinical Oncology

2008 - Present

AACR Program Organizing Committee

2003

American Association for the Advancement of Science

1994 - 2003

American Association for Cancer Research

1987 - Present

European Organization for Research on Treatment of Cancer (EORTC): Pharmacokinetics and Molecular Mechanism (PAMM) Group

1981 - Present

British Association for Cancer Research

1981 - 2004

Selected Presentations & Talks

Local Presentations

2005. Speaker, Faculty Compensation Committee: SAP: Facts and Fiction. Conference. Speaker, Faculty Compensation Committee: SAP: Facts and Fiction. Houston, TX, US.
2005. Speaker, Faculty Compensation Committee: Benchmark Comparisons. Conference. Speaker, Faculty Compensation Committee: Benchmark Comparisons. Houston, TX, US.
2005. Invited Speaker, Targeting Wild-Type p53 in Refractory Cancers. Conference. Invited Speaker, Targeting Wild-Type p53 in Refractory Cancers. Houston, TX, US.
2003. Speaker, Faculty Compensation Sub-Committee: Review of Salary Analysis for Faculty and Administrators. Conference. Speaker, Faculty Compensation Sub-Committee: Review of Salary Analysis for Faculty and Administrators. Houston, TX, US.
2001. Speaker, Faculty Compensation Advisory Committee: Faculty Compensation Project – The Towers Perrin Report. Conference. Speaker, Faculty Compensation Advisory Committee: Faculty Compensation Project – The Towers Perrin Report. Houston, TX, US.
1999. Speaker, Faculty Compensation Advisory Committee: Faculty Compensation Project Update. Conference. Speaker, Faculty Compensation Advisory Committee: Faculty Compensation Project Update. Houston, TX, US.
1998. Speaker, Faculty Compensation Advisory Committee: Faculty Compensation Project. Conference. Speaker, Faculty Compensation Advisory Committee: Faculty Compensation Project. Houston, TX, US.

National Presentations

2024. Cancer Research. Conference. AACR Annual Meeting 2024. San Diego, CA, US.
2023. Cancer Research. Conference. AACR Annual Meeting 2023. Orlando, FL, US.
2020. Cancer Research. Conference. 2020 Virutal Annual AACR Meeting, US.
2019. Cancer Research. Conference. Cancer Research. Atlanta, GA, US.
2003. Speaker and Session Chair, Mechanism of Platinum Resistance. Conference. AACR Poster Discussion Presentation. Washington, DC, US.
1999. Invited Speaker, Developing new cancer therapeutic agents to target p53 dysfunction. Conference. Cancer Therapeutics Discovery Program Scientific Symposium. Houston, TX, US.
1997. Circumvention of DNA damage tolerance through activation of p53 Function. Conference. Cancer Therapeutics Discovery Program Workshop IV. Houston, TX, US.
1996. Invited Speaker, Development of platinum-based drugs. Conference. Past Success and Future Strategy, Cancer Therapeutics Discovery Program Workshop II. Houston, TX, US.
1996. Invited Speaker, Development of carboplatin and RMP-7 combination for brain tumors. Conference. Workshop on Novel Applications of Carboplatin. Tampa, FL, US.
1994. Invited Speaker, Clinical pharmacology of enloplatin. Conference. American College of Clinical Pharmacology’s 23rd Annual Meeting, October 6-8. Orlando, FL, US.
1992. Section of Drug Metabolism & Disposition. Conference. Lilly Research Laboratories. Indianapolis, IN, US.
1991. Invited Speaker, Pharmacokinetic-pharmacodynamic considerations in the development of platinum complexes. Conference. Workshop on New Platinum Complexes. Pearl River, NY, US.
1991. Medical Research Division. Conference. Lederle Laboratories. Pearl River, NY, US.
1985. Invited Speaker, Aspects of the experimental pharmacology of carboplatin. Conference. Workshop on New Antitumor Agents in Development. Philadelphia, PA, US.

International Presentations

2023. Paradox of the wild P53 in refractory ovarian carcinoma. Conference. Paradox of the wild P53 in refractory ovarian carcinoma. Mar del Plata, AR.
2015. Mechanism-based design of platinum-based complexes as therapeutic agents for targeting refractory cancers, Exploring New Avenues in Medicinal Chemistry. Conference. Mechanism-based design of platinum-based complexes as therapeutic agents for targeting refractory cancers, Exploring New Avenues in Medicinal Chemistry, PK.
2011. The Good, the Bad and the Ugly Sides of the p53 Tumor Suppressor in Cancer Therapy. Conference. 4th International Conference of Translational Cancer Research. Udaipur, IN.
2010. The paradox in cell cycle effects of cisplatin: Failure of tumor cells to accumulate in G1 following activation of G1-checkpoint. Conference. 15th World Congress on Advances in Oncology. Loutraki, GR.
2008. A Rational Microarray Approach to Investigate the Paradox of Wild-Type p53 in Refractory Cancers. Conference. 13th World Congress on Advances in Oncology and 11th International Symposium on Molecular Medicine. Hersonissos, GR.
2004. Invited Speaker, The Mechanism of Selective Inhibition of G1-Phase Cdk4/cyclin D and Cdk2/cyclin E Complexes in Response to Checkpoint Activation by an Analog of Cisplatin. Conference. 9th World Congress on Advances in Oncology and 7th International Symposium on Molecular Medicine, October 16-19. Crete, GR.
2000. Invited Speaker, Therapeutic Antitumor Agents Targeting p53, 5th World Congress on Advances in Oncology. Conference. 3rd International Symposium on Molecular Medicine. Crete, GR.
1999. Invited Speaker, Chemical and biochemical approaches designed to circumvent cisplatin Resistance. Conference. 4th World Congress on Advances in Oncology and 2nd International Symposium on Molecular Medicine, October 7-9. Athens, GR.
1999. Invited Speaker, Relationship between DNA damage tolerance and p53 functional status for cisplatin and 1R,2R-diaminocyclohexane-diacetato-dichloro-platinum(IV) (DACH-Acetato-Pt). Conference. 8th International Symposium on Platinum Metal Coordination Compounds in Cancer Chemotherapy. March 29-31. Oxford, GB.
1998. Invited Speaker, The role of p53 in the onset and circumvention of cisplatin resistance. Conference. 3rd World Congress on Advances in Oncology and 1st International Symposium on Molecular Medicine, October 15-17. Crete, GR.
1992. Invited Speaker, Platinum-based antitumor agents in development. Conference. Second International Symposium on Transition Metals in Chemotherapy, September 22-24. Bristol, GB.
1990. Invited Speaker, Pharmacologically guided development of platinum complexes. Conference. 15th International Cancer Congress (UICC), August 16-22. Hamburg, DE.
1990. Invited Speaker, Pharmacokinetics of platinum complexes. Conference. First International Conference on Platinum Complexes and Liposomes in the Treatment of Cancer. Barcelona, ES.
1989. Invited Speaker, Analytical techniques in pharmacological studies of platinum-containing antitumor agents. Conference. XXVII International Conference on Coordination Chemistry: Symposium on Metal Complexes in the Detection and Treatment of Cancer, July 10-14. Marysville, AU.
1986. Invited Speaker, Species difference in drug absorption, distribution and elimination as a pitfall in using preclinical pharmacokinetics for toxicity prediction in man. Conference. EORTC Pharmacokinetics and Metabolism Group Symposium: Prediction of Toxicity in Phase I Trials Based on Preclinical and Clinical Pharmacokinetics, June 12-14. Edinburgh, GB.
1985. Invited Speaker, Tissue solubilization in hyamine hydroxide for the flameless atomic absorption spectrophotometric determination of platinum. Conference. International Cancer Research Symposium: Biochemical Mechanisms of Platinum Antitumour Drugs, July 3-5. Uxbridge.
1985. Invited Speaker, Renal pharmacokinetics and toxicity of cisplatin and carboplatin in animals. Conference. International Cancer Research Symposium: Biochemical Mechanisms of Platinum Antitumour Drugs, July 3-5. Uxbridge.
1983. Invited Speaker, Biliary excretion, renal handling and red cell uptake of cisplatin and CBDCA. Conference. 4th International Symposium on Platinum Coordination Complexes in Cancer Chemotherapy. Burlington, US.

Formal Peers

2012. Tumor Suppressor p53 and Drug Response: The Good, The Bad and The Ugly. Invited. Ontario, CA.
2005. Speaker, Wild-Type p53 as a Checkpoint Response and Therapeutic Target in Refractory Cancers. Invited. Santa Clara, CA, US.
1998. Lecturer. Visiting. London, GB.
1994. Visiting Professor. Visiting. Fukuoka, JP.
1992. Pharmacology Seminars. Invited. Houston, TX, US.
1989. Department of Pharmacology. Invited. Houston, TX, US.
1987. Pharmacology Seminar Series. Invited. Rochester, MN, US.
1981. Lecturer. Visiting. London, GB.

Less

Grant & Contract Support

Date:	2026 - 2030
Title:	Recredentialing Wild-Type p53 in Advanced Ovarian Cancer
Funding Source:	Department of Defense
Role:	PI
ID:	OC250495

Date:	2026 - 2031
Title:	Leveraging Therapeutic Vulnerability in Refractory Ovarian Cancer
Funding Source:	NIH/NCI
Role:	PI
ID:	FP00028240

Date:	2026 - 2028
Title:	Priming refractory ovarian cancer for synthetic lethal interactions with PARP inhibitors
Funding Source:	NIH/NCI
Role:	PI
ID:	1R21CA307903-01A1

Date:	2025 - 2028
Title:	Mechanism-Based Targeting of Wild-Type p53 in Refractory Ovarian Cancer
Funding Source:	CPRIT
Role:	PI
ID:	RP260251

Date:	2025 - 2027
Title:	Priming refractory ovarian cancer for synthetic lethal interactions with PARP inhibitors
Funding Source:	NIH/NCI
Role:	PI
ID:	1R21CA307903-01

Date:	2024 - 2027
Title:	RA230306 - Mechanism-Based Targeting of MDM2 and G1-CDK for Therapy of Rare Refractory Ovarian Cancer Subtypes
Funding Source:	Department of Defense (DOD)
Role:	PI

Date:	2024 - 2026
Title:	Utility of PARP Inhibitors in Rare Refractory Ovarian Cancer Sub-Types
Funding Source:	NIH/NCI
Role:	PI

Date:	2023 - 2025
Title:	Targeting MDM4 in Rare Refractory Ovarian Cancer Sub-Types
Funding Source:	NIH/NCI
Role:	PI
ID:	GRANT13803145

Date:	2023 - 2028
Title:	Unmasking Conserved Phospho-sites for Wild-type p53 Activation in Refractory Cancers
Funding Source:	NIH/NCI
Role:	PI
ID:	1R01CA279055-01

Date:	2022 - 2024
Title:	Molecular Mechanism of OxaliTex
Funding Source:	Sponsored Research Agreement
Role:	PI
ID:	RCTS# LS2022-00060252-RP

Date:	2021 - 2026
Title:	Targeting wild-type p53 in refractory cancers
Funding Source:	NIH/NCI
Role:	PI
ID:	1R01CA266508-01

Date:	2021 - 2024
Title:	RA200395 - Rational restoration of p53-dependent antitumor drug response in chemoresistant rare ovarian cancer subtype
Funding Source:	Department of Defense (DOD)
Role:	PI
ID:	GRANT13249696

Date:	2021 - 2022
Title:	Eclipse High Performance Mass Spectrometer for Proteomics
Funding Source:	NIH/NIGMS
Role:	Major User
ID:	1 S10 OD030382-01

Date:	2020 - 2025
Title:	Role of DCLK1 in Promoting Chemo Resistance in Ovarian Cancer
Funding Source:	NIH/NCI
Role:	Mentor
ID:	FP00008617

Date:	2020 - 2022
Title:	Targeting MDM2 in Mesothelioma
Funding Source:	DOD/Congressionally Directed Medical Research Programs (DOD/CDMRP)
Role:	PI
ID:	CA190615

Date:	2020 - 2023
Title:	Pharmacologic modulation of p53 dynamics to enhance therapeutic response in refractory cancers
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	PI
ID:	RP200344

Date:	2019 - 2022
Title:	OC180080: Enhanced Therapeutic Targeting of Mitosis in Ovarian Cancer
Funding Source:	DOD/Congressionally Directed Medical Research Programs (DOD/CDMRP)
Role:	Co-I
ID:	OC180080

Date:	2019 - 2022
Title:	BC180537: Enhanced Therapeutic Targeting of Cell Cycle in Breast Cancer
Funding Source:	DOD/Congressionally Directed Medical Research Programs (DOD/CDMRP)
Role:	Co-I
ID:	BC180537

Date:	2019 - 2024
Title:	Targeting Wild-Type p53 in Chemoresistant Rare Ovarian Cancers
Funding Source:	NIH/NCI
Role:	PI
ID:	1R01CA244385-01

Date:	2019 - 2024
Title:	Wip1 Phosphatase and Platinum Drug Response
Funding Source:	NIH/NCI
Role:	PI
ID:	1 R01 CA238289-01

Date:	2019 - 2022
Title:	Enhancing mitotic cell death by a novel drug combination
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	Co-I

Date:	2019 - 2020
Title:	An Orbitrap Fusion Lumos for Advanced Proteomics and Metabolomics - instrumentation grant program
Funding Source:	NIH/NCI
Role:	Minor User
ID:	1 S10 OD026894-01

Date:	2018 - 2023
Title:	Enhancing mitotic cell death in cancer therapy
Funding Source:	NIH/NCI
Role:	Co-I
ID:	GRANT12555118

Date:	2018 - 2023
Title:	Targeted Development of Platinum Drug Combinations
Funding Source:	NIH/NCI
Role:	PI
ID:	2R01CA160687-06

Date:	2017 - 2018
Title:	Synergizing a first-in-class DNA targeting agent with PARP inhibition for cisplatin-resistant ovarian cancer
Funding Source:	NIH/NCI Small Business Technology Transfer (STTR)
Role:	Co-I

Date:	2017 - 2023
Title:	Cell Cycle Blockade and Therapeutic Sensitization
Funding Source:	NIH/NCI
Role:	PI
ID:	5R01CA211975

Date:	2017 - 2018
Title:	Activation of dysfunctional wild-type p53 in drug-resistant non-small cell lung cancer as a therapeutic strategy
Funding Source:	DOD/Congressionally Directed Medical Research Programs (DOD/CDMRP)
Role:	PI
ID:	LC160609

Date:	2017 - 2022
Title:	Cell Cycle Blockade and Therapeutic Sensitization
Funding Source:	NIH/NCI
Role:	PI
ID:	1R01CA211975-01

Date:	2016 - 2019
Title:	Selective protection of cisplatin-induced renal injury in the therapy of refractory ovarian cancers
Funding Source:	DOD/Congressionally Directed Medical Research Programs (DOD/CDMRP)
Role:	PI
ID:	PR161325

Date:	2016 - 2021
Title:	Targeting MDM4 in Chemoresistant Cancers
Funding Source:	NIH/NCI
Role:	PI
ID:	1R01CA205251-01

Date:	2016 - 2019
Title:	Rewiring the MDM4 Circuitry to Activate p53 in Chemoresistant Tumor Cells
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	PI
ID:	RP160469

Date:	2015 - 2018
Title:	Pre-IND Development of OxaliTex
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	PI
ID:	DP150087

Date:	2014 - 2015
Title:	Center for Inflammation Systems Pharmacology
Funding Source:	Methodist Hospital Research Institute
Role:	Co-I
ID:	1P50GM107611-01

Date:	2014 - 2017
Title:	Identification and Characterization of Novel Anti-Inflammatory Agents from Turmeric
Funding Source:	(Curcuma Longa)
Role:	PI

Date:	2014 - 2015
Title:	Targeted stabilization of wild-type p53 for lung cancer therapy
Funding Source:	DOD/Congressionally Directed Medical Research Programs (DOD/CDMRP)
Role:	PI

Date:	2014 - 2016
Title:	Activity of VAL-083 as a Novel Chemotherapy for TMZ-Resistant GBM Patients - NIH Small Business Technology Transfer (STTR)
Funding Source:	Dept of Energy/Del Mar Pharmaceuticals
Role:	PI

Date:	2014 - 2019
Title:	Checkpoint Response and Platinum Drug Sensitivity
Funding Source:	NIH/NCI
Role:	PI
ID:	RO1 CA127263

Date:	2014 - 2019
Title:	Core Project 3
Funding Source:	Computational Systems Biology-Center for Inflammation Systems Pharmacology
Role:	Co-PI
ID:	P50 GM107611-01

Date:	2013 - 2017
Title:	Biochemical and Molecular Pharmacology of VAL-083
Funding Source:	Del Mar Pharmaceuticals
Role:	PI

Date:	2012 - 2015
Title:	Cisplatin Resistance in Ovarian Cancer Harboring Wild-Type p53
Funding Source:	National Science Foundation (NSF)
Role:	Mentee - Michelle Martinez

Date:	2012 - 2014
Title:	The Underlying Basis for Supra-Resistance in Malignant Mesothelioma
Funding Source:	DOD/Congressionally Directed Medical Research Programs (DOD/CDMRP)
Role:	PI

Date:	2012 - 2014
Title:	CTR1 Transporter Dysregulation in Platinum Resistant NSCLC - Young Investigator Award, Conquer Cancer Foundation
Funding Source:	American Society of Clinical Oncology (ASCO)
Role:	Mentee -Kim

Date:	2011 - 2014
Title:	Preclinical Development of Texaphyrin-Platinum Conjugates
Funding Source:	CPRIT
Role:	Principal Investigator (Sub-Contractor)
ID:	RP120393 01

Date:	2011 - 2017
Title:	Targeted Development of Platinum Drugs
Funding Source:	NIH/NCI
Role:	PI
ID:	1R01CA160687-01

Date:	2011 - 2013
Title:	Development of Texaphyrin-Platinum Conjugates
Funding Source:	American Cancer Society (ACS)
Role:	Mentor

Date:	2010 - 2015
Title:	Platinum Resistance and the Tumor Suppresor p53
Funding Source:	NIH/NCI
Role:	PI
ID:	1 RO1 CA148741-01A1

Date:	2010 - 2011
Title:	Transrepression of Survivin as a Therapeutic Strategy in Advanced Breast Cancer
Funding Source:	DOD/Congressionally Directed Medical Research Programs (DOD/CDMRP)
Role:	PI
ID:	BC097172

Date:	2010 - 2013
Title:	Wild-type p53 as a target of therapy in malignant mesothelioma
Funding Source:	DOD/Congressionally Directed Medical Research Programs (DOD/CDMRP)
Role:	PI

Date:	2010 - 2015
Title:	Platinum Resistance and the Tumor Suppressor p53
Funding Source:	NIH/NCI
Role:	PI

Date:	2010 - 2014
Title:	Defective Activation of Wild-type p53 in Chemoresistant Cancers
Funding Source:	Cancer Prevention and Research Institute of Texas
Role:	PI

Date:	2009 - 2011
Title:	G1 Checkpoint Response in Advanced Breast Cancer
Funding Source:	DOD/Congressionally Directed Medical Research Programs (DOD/CDMRP)
Role:	PI

Date:	2009 - 2011
Title:	Defining the underlying mechanism of resistance in mesothelioma as a basis for novel therapy in this rare disease
Funding Source:	NIH/NCI
Role:	PI

Date:	2009 - 2010
Title:	Targeting wild-type p53 in refractory breast cancer
Funding Source:	DOD/Congressionally Directed Medical Research Programs (DOD/CDMRP)
Role:	PI
ID:	W81XWH-08-BCRP-CA

Date:	2009 - 2012
Title:	Endogenous wild-type p53 as a therapeutic target in cisplatin-resistant ovarian cancers
Funding Source:	DOD/Congressionally Directed Medical Research Programs (DOD/CDMRP)
Role:	PI
ID:	W81XWH-08-OCRP-IDA

Date:	2008 - 2010
Title:	Platinum-texaphyrin Cisplatin Conjugates and Drug Resistance Interactions
Funding Source:	CTT/TI-3D
Role:	Co-PI

Date:	2008 - 2013
Title:	Waf1/Cip1 as a Target of Therapy in Drug-Resistant Cells
Funding Source:	NIH/NCI
Role:	PI

Date:	2008 - 2009
Title:	Gene Expression Signatures to Define Deregulated Pathways in Refactory Ovarian Cancers
Funding Source:	Department of Defense (DOD)
Role:	PI

Date:	2008 - 2011
Title:	Status of p53-p21 Pathway and Therapeutic Response in Advanced Breast Cancer
Funding Source:	Department of Defense (DOD)
Role:	PI

Date:	2007 - 2008
Title:	Down-regulation of p21 Waf1/Cip1 Promoter Activity in Chemoresistant Breast Cancer
Funding Source:	Department of Defense (DOD)
Role:	PI

Date:	2007
Title:	Protein Kinase CK2 as a target in cisplatin-resistant epithelial ovarian cancers
Funding Source:	Department of Defense Ovarian Cancer Research Program OCRP06 Concept Award
Role:	PI

Date:	2007 - 2014
Title:	Checkpoint Response and Platinum Drug Sensitivity
Funding Source:	NIH/NCI
Role:	PI
ID:	RO1 CA127263

Date:	2006 - 2011
Title:	Clinical Pharmacology of L-NDDP
Funding Source:	Antigenics, Inc
Role:	PI
ID:	CS2006-00016259LE

Date:	2005 - 2010
Title:	Training of Academic Gynecologic Oncologists
Funding Source:	NIH/NCI
Role:	Mentor

Date:	2004 - 2009
Title:	Training for Academic Oncology
Funding Source:	NCI-NIH
Role:	Mentor
ID:	T32 CA-09666

Date:	2003 - 2008
Title:	Pharmacology and New Drug Development, CCSG Core Grant
Funding Source:	NIH/NCI
Role:	Co-Program Leader
ID:	P30 CA016672

Date:	2001 - 2007
Title:	Effects of DNA Damaging Agents on G2 Phase Checkpoint
Funding Source:	NIH/NCI
Role:	Co-I

Date:	2001 - 2005
Title:	Development of DACH-acetato-Pt for an IND Application
Funding Source:	MDACC CTDP Kleberg Drug Development Grant
Role:	Co-PI

Date:	2000 - 2005
Title:	Clinical Oncology Career Development Program
Funding Source:	NIH
Role:	Mentor

Date:	1999 - 2003
Title:	Therapy of Breast Tumor Cells Overexpressing c-erbB-2/neu
Funding Source:	Department of Defense Breast Cancer Research Program
Role:	PI

Date:	1999 - 2004
Title:	Circumvention of Cisplatin Resistance
Funding Source:	NCI
Role:	PI
ID:	RO1 CA82361

Date:	1999 - 2004
Title:	Training for Academic Oncology
Funding Source:	NCI-NIH
Role:	Mentor
ID:	T32 CA-09666

Date:	1999 - 2001
Title:	JAB1 as a Marker for Anticancer Drug Resistance
Funding Source:	UTMDACC PRS
Role:	Co-I

Date:	1999 - 2003
Title:	Mechanistic Development of Platinum-Based Drugs
Funding Source:	NCI
Role:	PI
ID:	RO1 CA77332

Date:	1998 - 2002
Title:	Phase II/III Clinical Trials of Anticancer Agents
Funding Source:	NCI
Role:	Co-I
ID:	UO1 CA70172

Date:	1998 - 2001
Title:	c-erbB-2 Overexpression and Platinum Activity in Refractory Ovarian Tumors
Funding Source:	Sandra G Davis Ovarian Cancer Research Fund
Role:	PI

Date:	1998 - 2003
Title:	Correlated Laboratory - Clinical Phase I Drug Development
Funding Source:	NCI
Role:	Co-I
ID:	5 UO1 CA62461

Date:	1997 - 1999
Title:	Pharmacology of Carboplatin in Combination with RMP-7 in the Treatment of Malignant Glioma in a Phase II Study
Funding Source:	Alkermes, Inc
Role:	PI
ID:	LS 97-031

Date:	1995 - 2000
Title:	Phase I Clinical Trials of Anticancer Agents
Funding Source:	NIH/NCI
Role:	Co-I
ID:	5 UO1 CA62461

Selected Publications

Peer-Reviewed Articles

He G, Thiabaud GD, Shelton KA, Segura LJ, Arambula JF, Sessler JL, Finch RA, Siddik ZH. Profiling the Preclinical Pharmacokinetics and Biodistribution of a Platinum(IV)-Based Oxaliplatin Prodrug OxaliTEX and Their Significance to Antitumor Response. Mol Pharm, 2025. e-Pub 2025. PMID: 41160639.
Calvert, AH, Newell, DR, Gumbrell, LA, O'Reilly, S, Burnell, M, Boxall, FE, Siddik, ZH, Judson, IR, Gore, M, Wiltshaw, E. Carboplatin dosage. Journal of Clinical Oncology 41(28):4453-4454, 2023. e-Pub 2023. PMID: 37757592.
Rodriguez-Aguayo C, Bayraktar E, Ivan C, Aslan B, Mai J, He G, Mangala LS, Jiang D, Nagaraja AS, Ozpolat B, Chavez-Reyes A, Ferrari M, Mitra R, Siddik ZH, Shen H, Yang X, Sood AK, Lopez-Berestein G. Corrigendum to "PTGER3 induces ovary tumorigenesis and confers resistance to cisplatin therapy through up-regulation Ras-MAPK/Erk-ETS1-ELK1/CFTR1 axis" [EBioMedicine 40 (2019) 290-304]. EBioMedicine 83:104194, 2022. e-Pub 2022. PMID: 35914489.
Subramaniam, B, Siddik, ZH, Hasima, N. Development and validation of a reversed-phase HPLC method for quantification of 1’-acetoxychavicol acetate content in a nanostructured lipid carrier formulation. Brazilian Journal of Pharmaceutical Sciences 58, 2022. e-Pub 2022.
Mangala LS, Zuzel V, Schmandt R, Leshane ES, Halder JB, Armaiz-Pena GN, Spannuth WA, Tanaka T, Shahzad MMK, Lin YG, Nick AM, Danes CG, Lee JW, Jennings NB, Vivas-Mejia PE, Wolf JK, Coleman RL, Siddik ZH, Lopez-Berestein G, Lutsenko S, Sood AK. Editor's Note: Therapeutic Targeting of ATP7B in Ovarian Carcinoma. Clin Cancer Res 27(15):4454, 2021. e-Pub 2021. PMID: 34341059.
Moreno-Smith M, Halder JB, Meltzer PS, Gonda TA, Mangala LS, Rupaimoole R, Lu C, Nagaraja AS, Gharpure KM, Kang Y, Rodriguez-Aguayo C, Vivas-Mejia PE, Zand B, Schmandt R, Wang H, Langley RR, Jennings NB, Ivan C, Coffin JE, Armaiz GN, Bottsford-Miller J, Kim SB, Halleck MS, Hendrix MJ, Bornman W, Bar-Eli M, Lee JS, Siddik ZH, Lopez-Berestein G, Sood AK. ATP11B mediates platinum resistance in ovarian cancer. J Clin Invest 131(7), 2021. e-Pub 2021. PMID: 33792569.
Hong B, Chapa V, Saini U, Modgil P, Cohn DE, He G, Siddik ZH, Sood AK, Yan Y, Selvendiran K, Pei G, Zhao Z, Yoo JY, Kaur B. Oncolytic HSV therapy modulates vesicular trafficking inducing cisplatin sensitivity and anti-tumor immunity. Clin Cancer Res 27(2):542-553, 2021. e-Pub 2021. PMID: 33087329.
He G, Xie X, Siddik ZH. Protein expression profiling identifies differential modulation of homologous recombination by platinum-based antitumor agents. Cancer Chemother Pharmacol 85(6):1129-1140, 2020. e-Pub 2020. PMID: 32468080.
Xie X, He G, Siddik ZH. Cisplatin in Combination with MDM2 Inhibition Downregulates Rad51 Recombinase in a Bimodal Manner to Inhibit Homologous Recombination and Augment Tumor Cell Kill. Mol Pharmacol 97(4):237-249, 2020. e-Pub 2020. PMID: 32063580.
Thiabaud G, He G, Sen S, Shelton KA, Baze WB, Segura L, Alaniz J, Munoz Macias R, Lyness G, Watts AB, Kim HM, Lee H, Cho MY, Hong KS, Finch R, Siddik ZH, Arambula JF, Sessler JL. Oxaliplatin Pt(IV) prodrugs conjugated to gadolinium-texaphyrin as potential antitumor agents. Proc Natl Acad Sci U S A 117(13):7021-7029, 2020. e-Pub 2020. PMID: 32179677.
Thiabaud G, Harden-Bull L, Ghang YJ, Sen S, Chi X, Bachman JL, Lynch VM, Siddik ZH, Sessler JL. Platinum(IV)-Ferrocene Conjugates and Their Cyclodextrin Host-Guest Complexes. Inorg Chem 58(12):7886-7894, 2019. e-Pub 2019. PMID: 31125214.
Rodriguez-Aguayo C, Bayraktar E, Ivan C, Aslan B, Mai J, He G, Mangala LS, Jiang D, Nagaraja AS, Ozpolat B, Chavez-Reyes A, Ferrari M, Mitra R, Siddik ZH, Shen H, Yang X, Sood AK, Lopez-Berestein G. PTGER3 induces ovary tumorigenesis and confers resistance to cisplatin therapy through up-regulation Ras-MAPK/Erk-ETS1-ELK1/CFTR1 axis. EBioMedicine 40:290-304, 2019. e-Pub 2019. PMID: 30655206.
Moreno-Smith M, Halder JB, Meltzer PS, Gonda TA, Mangala LS, Rupaimoole R, Lu C, Nagaraja AS, Gharpure KM, Kang Y, Rodriguez-Aguayo C, Vivas-Mejia PE, Zand B, Schmandt R, Wang H, Langley RR, Jennings NB, Ivan C, Coffin JE, Armaiz GN, Bottsford-Miller J, Kim SB, Halleck MS, Hendrix MJ, Bornman W, Bar-Eli M, Lee JS, Siddik ZH, Lopez-Berestein G, Sood AK. ATP11B mediates platinum resistance in ovarian cancer. J Clin Invest 128(7):3199, 2018. e-Pub 2018. PMID: 29809169.
Xie X, He G, Siddik ZH. Functional Activation of Mutant p53 by Platinum Analogues in Cisplatin-Resistant Cells Is Dependent on Phosphorylation. Mol Cancer Res 15(3):328-339, 2017. e-Pub 2017. PMID: 28031409.
Bhatt M, Ivan C, Xie X, Siddik ZH. Drug-dependent functionalization of wild-type and mutant p53 in cisplatin-resistant human ovarian tumor cells. Oncotarget 8(7):10905-10918, 2017. e-Pub 2017. PMID: 28038466.
Altaf M, Monim-Ul-Mehboob M, Kawde AN, Corona G, Larcher R, Ogasawara M, Casagrande N, Celegato M, Borghese C, Siddik ZH, Aldinucci D, Isab AA. New bipyridine gold(III) dithiocarbamate-containing complexes exerted a potent anticancer activity against cisplatin-resistant cancer cells independent of p53 status. Oncotarget 8(1):490-505, 2017. e-Pub 2017. PMID: 27888799.
Prasad S, Tyagi AK, Siddik ZH, Aggarwal BB. Curcumin-Free Turmeric Exhibits Activity against Human HCT-116 Colon Tumor Xenograft: Comparison with Curcumin and Whole Turmeric. Front Pharmacol 8:871, 2017. e-Pub 2017. PMID: 29311914.
Thiabaud G, McCall R, He G, Arambula JF, Siddik ZH, Sessler JL. Activation of Platinum(IV) Prodrugs By Motexafin Gadolinium as a Redox Mediator. Angew Chem Int Ed Engl 55(41):12626-31, 2016. e-Pub 2016. PMID: 27377046.
Xie X, Lozano G, Siddik ZH. Heterozygous p53V172F mutation in cisplatin-resistant human tumor cells promotes MDM4 recruitment and decreases stability and transactivity of p53. Oncogene 35(36):4798-4806, 2016. e-Pub 2016. PMID: 26876197.
Tsimberidou AM, Said R, Culotta K, Wistuba I, Jelinek J, Fu S, Falchook G, Naing A, Piha-Paul S, Zinner R, Siddik ZH, He G, Hess K, Stewart DJ, Kurzrock R, Issa JP. Phase I study of azacitidine and oxaliplatin in patients with advanced cancers that have relapsed or are refractory to any platinum therapy. Clin Epigenetics 7(1):29, 2015. e-Pub 2015. PMID: 25806091.
Thiabaud G, Arambula JF, Siddik ZH, Sessler JL. Photoinduced reduction of Pt(IV) within an anti-proliferative Pt(IV)-texaphyrin conjugate. Chemistry 20(29):8942-7, 2014. e-Pub 2014. PMID: 24961491.
Kim ES, Tang X, Peterson DR, Kilari D, Chow CW, Fujimoto J, Kalhor N, Swisher SG, Stewart DJ, Wistuba II, Siddik ZH. Copper transporter CTR1 expression and tissue platinum concentration in non-small cell lung cancer. Lung Cancer 85(1):88-93, 2014. e-Pub 2014. PMID: 24792335.
Preihs C, Arambula JF, Magda D, Jeong H, Yoo D, Cheon J, Siddik ZH, Sessler JL. Recent Developments in Texaphyrin Chemistry and Drug Discovery. Inorg Chem 52(21):12184-12192, 2013. e-Pub 2013. PMID: 23557113.
He G, Kuang J, Koomen J, Kobayashi R, Khokhar AR, Siddik ZH. Recruitment of trimeric proliferating cell nuclear antigen by G1-phase cyclin-dependent kinases following DNA damage with platinum-based antitumor agents. Br J Cancer 109(9):2378-88, 2013. e-Pub 2013. PMID: 24104967.
Moreno-Smith M, Halder JB, Meltzer PS, Gonda TA, Mangala LS, Rupaimoole R, Lu C, Nagaraja AS, Gharpure KM, Kang Y, Rodriguez-Aguayo C, Vivas-Mejia PE, Zand B, Schmandt R, Wang H, Langley RR, Jennings NB, Ivan C, Coffin JE, Armaiz GN, Bottsford-Miller J, Kim SB, Halleck MS, Hendrix MJ, Bornman W, Bar-Eli M, Lee JS, Siddik ZH, Lopez-Berestein G, Sood AK. ATP11B mediates platinum resistance in ovarian cancer. J Clin Invest 123(5):2119-30, 2013. e-Pub 2013. PMID: 23585472.
Moreno-Smith M, Lee SJ, Lu C, Nagaraja AS, He G, Rupaimoole R, Han HD, Jennings NB, Roh JW, Nishimura M, Kang Y, Allen JK, Armaiz GN, Matsuo K, Shahzad MM, Bottsford-Miller J, Langley RR, Cole SW, Lutgendorf SK, Siddik ZH, Sood AK. Biologic effects of dopamine on tumor vasculature in ovarian carcinoma. Neoplasia 15(5):502-10, 2013. e-Pub 2013. PMID: 23633922.
Kim ES, Lee JJ, He G, Chow CW, Fujimoto J, Kalhor N, Swisher SG, Wistuba II, Stewart DJ, Siddik ZH. Tissue platinum concentration and tumor response in non-small-cell lung cancer. J Clin Oncol 30(27):3345-52, 2012. e-Pub 2012. PMID: 22891266.
Arambula JF, Sessler JL, Siddik ZH. A texaphyrin-oxaliplatin conjugate that overcomes both pharmacologic and molecular mechanisms of cisplatin resistance in cancer cells. Medchemcomm 3(10):1275-1281, 2012. e-Pub 2012. PMID: 23936624.
Le XF, Mao W, He G, Claret FX, Xia W, Ahmed AA, Hung MC, Siddik ZH, Bast RC. The role of p27(Kip1) in dasatinib-enhanced paclitaxel cytotoxicity in human ovarian cancer cells. J Natl Cancer Inst 103(18):1403-22, 2011. e-Pub 2011. PMID: 21813412.
He G, Kuang J, Khokhar AR, Siddik ZH. The impact of S- and G2-checkpoint response on the fidelity of G1-arrest by cisplatin and its comparison to a non cross-resistant platinum (IV) analog. Gynecol Oncol 122(2):402-409, 2011. e-Pub 2011. PMID: 21592546.
Arambula JF, Sessler JL, Siddik ZH. Overcoming biochemical pharmacologic mechanisms of platinum resistance with a texaphyrin-platinum conjugate. Bioorg Med Chem Lett 21(6):1701-5, 2011. e-Pub 2011. PMID: 21345675.
Preihs C, Arambula JF, Lynch VM, Siddik ZH, Sessler JL. Bismuth- and lead-texaphyrin complexes: towards potential a-core emitters for radiotherapy. Chem Commun (Camb) 46(42):7900-2, 2010. e-Pub 2010. PMID: 20922235.
Kurokawa T, He G, Siddik ZH. Protein kinase inhibitors emodin and dichloro-ribofuranosylbenzimidazole modulate the cellular accumulation and cytotoxicity of cisplatin in a schedule-dependent manner. Cancer Chemother Pharmacol 65(3):427-36, 2010. e-Pub 2010. PMID: 19529937.
Rowe RW, Strebel FR, Proett JM, Deng W, Chan D, He G, Siddik Z, Bull JM. Fever-range whole body thermotherapy combined with oxaliplatin: A curative regimen in a pre-clinical breast cancer model. Int J Hyperthermia 26(6):565-576, 2010. e-Pub 2010. PMID: 20707651.
Arambula JF, Sessler JL, Fountain ME, Wei WH, Magda D, Siddik ZH. Gadolinium Texaphyrin (Gd-Tex)-Malonato-Platinum Conjugates: Synthesis and Comparison with Carboplatin in Normal and Pt-Resistant Cell Lines. Dalton Trans(48):10834-40, 2009. e-Pub 2009. PMID: 20023913.
Mangala LS, Zuzel V, Schmandt R, Leshane ES, Halder JB, Armaiz-Pena GN, Spannuth WA, Tanaka T, Shahzad MM, Lin YG, Nick AM, Danes CG, Lee JW, Jennings NB, Vivas-Mejia PE, Wolf JK, Coleman RL, Siddik ZH, Lopez-Berestein G, Lutsenko S, Sood AK. Therapeutic Targeting of ATP7B in Ovarian Carcinoma. Clin Cancer Res 15(11):3770-80, 2009. e-Pub 2009. PMID: 19470734.
Chen HH, Song IS, Hossain A, Choi MK, Yamane Y, Liang ZD, Lu J, Wu LY, Siddik ZH, Klomp LW, Savaraj N, Kuo MT. Elevated glutathione levels confer cellular sensitization to cisplatin toxicity by up-regulation of copper transporter hCtr1. Mol Pharmacol 74(3):697-704, 2008. e-Pub 2008. PMID: 18523133.
Lu Y, Li X, Liang K, Luwor R, Siddik ZH, Mills GB, Mendelsohn J, Fan Z. Epidermal Growth Factor (EGF) Receptor Ubiquitination as a Mechanism of Acquired Resistance to the Anti-EGF Receptor Monoclonal Antibody Cetuximab. Cancer Res 67(17):8240-7, 2007. e-Pub 2007. PMID: 17804738.
He G, Kuang J, Huang Z, Koomen J, Kobayashi R, Khokhar AR, Siddik ZH. Upregulation of p27 and its inhibition of CDK2/cyclin E activity following DNA damage by a novel platinum agent are dependent on the expression of p21. Br J Cancer 95(11):1514-24, 2006. e-Pub 2006. PMID: 17088910.
He G, Siddik ZH, Huang Z, Wang R, Koomen J, Kobayashi R, Khokhar AR, Kuang J. Induction of p21 by p53 following DNA damage inhibits both Cdk4 and Cdk2 activities. . Oncogene 24(18):2929-2943, 2005. e-Pub 2005. PMID: 15735718.
Ali MS, Khan SR, Ojima H, Guzman IY, Whitmire KH, Siddik ZH, Khokhar AR. Model platinum nucleobase and nucleoside complexes and antitumor activity: X-ray crystal structure of [Pt(IV)(trans-1R,2R-diaminocyclohexane)trans-(acetate)2(9-ethylguanine)Cl]NO3.H2O. . J Inorg Biochem 99(3):795-804, 2005. e-Pub 2005. PMID: 15708801.
Mujoo K, Watanabe M, Khokhar AR, Siddik ZH. Increased sensitivity of a metastatic model of prostate cancer to a novel tetravalent platinum analog. Prostate 62(1):91-100, 2005. e-Pub 2005. PMID: 15389812.
Song IS, Savaraj N, Siddik ZH, Liu P, Wei Y, Wu CJ, Kuo MT. Role of human copper transporter Ctr1 in the transport of platinum-based antitumor agents in cisplatin-sensitive and cisplatin-resistant cells. Mol Cancer Ther 3(12):1543-9, 2004. e-Pub 2004. PMID: 15634647.
Mujoo K, Watanabe M, Nakamura J, Khokhar AR, Siddik ZH. Status of p53 phosphorylation and function in sensitive and resistant human cancer models exposed to platinum-based DNA damaging agents. J Cancer Res Clin Oncol 129(12):709-18, 2003. e-Pub 2003. PMID: 14513366.
Verschraegen CF, Kumagai S, Davidson R, Feig B, Mansfield P, Lee SJ, Maclean DS, Hu W, Khokhar AR, Siddik ZH. Phase I clinical and pharmacological study of intraperitoneal cis-bis-neodecanoato( trans- R, R-1, 2-diaminocyclohexane)-platinum II entrapped in multilamellar liposome vesicles. J Cancer Res Clin Oncol 129(10):549-55, 2003. e-Pub 2003. PMID: 14513369.
Mansouri A, Ridgway LD, Korapati AL, Zhang Q, Tian L, Wang Y, Siddik ZH, Mills GB, Claret FX. Sustained activation of JNK/p38 MAPK pathways in response to cisplatin leads to Fas ligand induction and cell death in ovarian carcinoma cells. J Biol Chem 278(21):19245-56, 2003. e-Pub 2003. PMID: 12637505.
Mukhopadhyay U, Thurston J, Whitmire KH, Siddik ZH, Khokhar AR. Preparation, characterization, and antitumor activity of new cisplatin analogues with 1-methyl-4-(methylamino)piperidine: crystal structure of [PtII(1-methyl-4-(methylamino) piperidine)(oxalate)]. J Inorg Biochem 94(1-2):179-85, 2003. e-Pub 2003. PMID: 12620689.
Kuang J, He G, Huang Z, Khokhar AR, Siddik ZH. Bimodal effects of 1R,2R-diaminocyclohexane(trans-diacetato)(dichloro)platinum(IV) on cell cycle checkpoints. Clin Cancer Res 7(11):3629-39, 2001. e-Pub 2001. PMID: 11705886.
Ali Khan SR, Huang S, Shamsuddin S, Inutsuka S, Whitmire KH, Siddik ZH, Khokhar AR. Synthesis, characterization and cytotoxicity of new platinum(IV) axial carboxylate complexes: crystal structure of potential antitumor agent [PtIV(trans-1R,2R-diaminocyclohexane)trans(acetate)2Cl2]. Bioorg Med Chem 8(3):515-21, 2000. e-Pub 2000. PMID: 10732967.
Donato NJ, Perez M, Kang H, Siddik ZH, Ling YH, Perez-Soler R. EGF receptor and p21WAF1 expression are reciprocally altered as ME-180 cervical carcinoma cells progress from high to low cisplatin sensitivity. Clin Cancer Res 6(1):193-202, 2000. e-Pub 2000. PMID: 10656450.
Furui T, LaPushin R, Mao M, Khan H, Watt SR, Watt MA, Lu Y, Fang X, Tsutsui S, Siddik ZH, Bast RC, Mills GB. Overexpression of edg-2/vzg-1 induces apoptosis and anoikis in ovarian cancer cells in a lysophosphatidic acid-independent manner. Clin Cancer Res 5(12):4308-18, 1999. e-Pub 1999. PMID: 10632375.
Ali MS, Whitmire KH, Toyomasu T, Siddik ZH, Khokhar AR. Preparation, characterization, and antitumor activity of new cisplatin analogs with homopiperazines: crystal structure of [PtII(1-methylhomopiperazine)(methylmalonato)].2H2O. J Inorg Biochem 77(3-4):231-8, 1999. e-Pub 1999. PMID: 10643661.
Hagopian GS, Mills GB, Khokhar AR, Bast RC, Siddik ZH. Expression of p53 in cisplatin-resistant ovarian cancer cell lines: modulation with the novel platinum analogue (1R, 2R-diaminocyclohexane)(trans-diacetato)(dichloro)-platinum(IV). Clin Cancer Res 5(3):655-63, 1999. e-Pub 1999. PMID: 10100719.
Yoshida M, Khokhar AR, Siddik ZH. Cytotoxicity and tolerance to DNA adducts of alicyclic mixed amine platinum(II) homologs in tumor models sensitive and resistant to cisplatin or tetraplatin. Oncol Rep 5(5):1281-7, 1998. e-Pub 1998. PMID: 9683851.
Shamsuddin S, Santillan CC, Stark JL, Whitmire KH, Siddik ZH, Khokhar AR. Synthesis, characterization, and antitumor activity of new platinum(IV) trans-carboxylate complexes: crystal structure of [Pt(cis-1,4-DACH)trans-(acetate)2Cl2]. J Inorg Biochem 71(1-2):29-35, 1998. e-Pub 1998. PMID: 9755489.
Siddik ZH, Mims B, Lozano G, Thai G. Independent pathways of p53 induction by cisplatin and X-rays in a cisplatin-resistant ovarian tumor cell line. Cancer Res 58(4):698-703, 1998. e-Pub 1998. PMID: 9485023.
Kudelka AP, Siddik ZH, Tresukosol D, Edwards CL, Freedman RS, Madden TL, Rastogi R, Hord M, Kim EE, Tornos C, Mante R, Kavanagh JJ. A phase II and pharmacokinetic study of enloplatin in patients with platinum refractory advanced ovarian carcinoma. Anticancer Drugs 8(7):649-56, 1997. e-Pub 1997. PMID: 9311439.
Perez-Soler R, Shin DM, Siddik ZH, Murphy WK, Huber M, Lee SJ, Khokhar AR, Hong WK. Phase I clinical and pharmacological study of liposome-entrapped NDDP administered intrapleurally in patients with malignant pleural effusions. Clin Cancer Res 3(3):373-9, 1997. e-Pub 1997. PMID: 9815694.
Khokhar AR, al-Baker S, Shamsuddin S, Siddik ZH. Chemical and biological studies on a series of novel (trans-(1R,2R)-, trans-(1S,2S)-, and cis-1,2-diaminocyclohexane)platinum(IV) carboxylate complexes. J Med Chem 40(1):112-6, 1997. e-Pub 1997. PMID: 9016335.
Kantarjian HM, Beran M, O'Brien S, Robertson L, Siddik Z, Yoshida M, Yang LY, Rios MB, Keating MJ, Meyer M, et al. Evaluation of CI-973, a platinum analogue, in refractory or relapsed acute leukemia. Leukemia 10(3):396-401, 1996. e-Pub 1996. PMID: 8642853.
Shamsuddin S, Takahashi I, Siddik ZH, Khokhar AR. Synthesis, characterization, and antitumor activity of a series of novel cisplatin analogs with cis-1,4-diaminocyclohexane as nonleaving amine group. J Inorg Biochem 61(4):291-301, 1996. e-Pub 1996. PMID: 8867456.
Shamsuddin S, Al-Baker S, Siddik ZH, Khokhar AR. Synthesis and antitumor activity of new trans-1R,2R-diaminocyclohexaneplatinum(II) complexes containing disubstituted sulfide as a leaving group. . Inorg Chim Acta 241:101-104, 1996. e-Pub 1996.
Klostergaard J, Leroux ME, Hsu HA, Hsi BP, Siddik ZH, Danhauser LL, Tomasovic SP. Multi-chemothermoimmunotherapy for human colon adenocarcinoma in vitro. Cancer Chemother Pharmacol 37(3):235-41, 1996. e-Pub 1996. PMID: 8529283.
Kudelka AP, Siddik ZM, Balat O, Kavanagh JJ. Carboplatin dosimetry in renal failure. J Clin Oncol 13(8):2147-8, 1995. e-Pub 1995. PMID: 7636563.
Davidson BS, Izzo F, Cromeens DM, Stephens LC, Siddik ZH, Curley SA. Collagen matrix cisplatin prevents local tumor growth after margin-positive resection. J Surg Res 58(6):618-24, 1995. e-Pub 1995. PMID: 7791337.
Wondergem J, Strebel FR, Stephens LC, Siddik ZH, Bull JM. Chronic effect of whole-body hyperthermia combined simultaneously with cis-diamminedichloroplatinum (II) on normal tissue in rat. Int J Hyperthermia 11(1):37-47, 1995. e-Pub 1995. PMID: 7714369.
Curley SA, Fuhrman GM, Siddik ZH, Davidson BS, Cleary KR, Cromeens DM. Direct intratumoral injection of a novel collagen matrix gel and cisplatin effectively controls experimental liver tumors. Cancer Res Ther Control 4:247-254, 1995. e-Pub 1995.
Siddik ZH, Thai G, Yoshida M, Zhang YP, Khokhar AR. Tetravalent platinum complexes with ammine/amine carrier ligand configuration: circumvention of platinum resistance in vivo. Anticancer Drug Des 9(6):495-509, 1994. e-Pub 1994. PMID: 7880375.
Yoshida M, Khokhar AR, Siddik ZH. Circumvention of platinum resistance: structure-activity relationship for homologous series of ammine/amine platinum(II) complexes in L1210 cell lines. Anticancer Drug Des 9(5):425-34, 1994. e-Pub 1994. PMID: 7945726.
Yoshida M, Khokhar AR, Siddik ZH. Axial ligands and alicyclic ring size modulate the activity and biochemical pharmacology of ammine/cycloalkylamine-platinum(IV) complexes in tumor cells resistant to cis-diamminedichloroplatinum(II) or trans-1R,2R-1S,2S-diaminocyclohexanetetrachloroplatinum(IV). Cancer Res 54(17):4691-7, 1994. e-Pub 1994. PMID: 8062266.
Yoshida M, Khokhar AR, Kido Y, Ali-Osman F, Siddik ZH. Correlation of total and interstrand DNA adducts in tumor and kidney with antitumor efficacies and differential nephrotoxicities of cis-ammine/cyclohexylamine-dichloroplatinum(II) and cisplatin. Biochem Pharmacol 48(4):793-9, 1994. e-Pub 1994. PMID: 8080453.
Yoshida M, Khokhar AR, Siddik ZH. Biochemical pharmacology of homologous alicyclic mixed amine platinum(II) complexes in sensitive and resistant tumor cell lines. Cancer Res 54(13):3468-73, 1994. e-Pub 1994. PMID: 8012968.
Siddik ZH, al-Baker S, Thai G, Khokhar AR. Modulatory effect of axial and equatorial ligands on antitumor activities of trans-1R,2R-diaminocyclohexane platinum(IV) complexes. Anticancer Drug Des 9(2):139-51, 1994. e-Pub 1994. PMID: 8166929.
Kido Y, Khokhar AR, Siddik ZH. Glutathione-mediated modulation of tetraplatin activity against sensitive and resistant tumor cells. Biochem Pharmacol 47(9):1635-42, 1994. e-Pub 1994. PMID: 8185678.
Khokhar AR, al-Baker S, Siddik ZH. Synthesis and antitumor activity of 1,2-diaminocyclohexane platinum(IV) complexes. J Inorg Biochem 54(1):39-47, 1994. e-Pub 1994. PMID: 8151310.
Kido Y, Khokhar AR, Yoshida M, Thai GW, Siddik ZH. Pharmacokinetics of tetraplatin administered intraperitoneally with reduced glutathione in mice. Drug Metab Dispos 22(2):312-7, 1994. e-Pub 1994. PMID: 8013287.
Khokhar AR, Xu Q, Siddik ZH. Synthesis, characterization, and antitumor activity of amine platinum(II) and (IV) tellurate complexes. J Inorg Biochem 53(4):295-301, 1994. e-Pub 1994. PMID: 8169608.
Yoshida M, Khokhar AR, Zhang YP, Thai G, Siddik ZH. Kinetics of tissue disposition of cis-ammine/cyclohexylamine-dichloroplatinum(II) and cisplatin in mice bearing FSaIIC tumors. Cancer Chemother Pharmacol 35(1):38-44, 1994. e-Pub 1994. PMID: 7987975.
Siddik ZH, Thai G, Yoshida M, Zhang YP, Khokhar AR. Ammine/amine platinum (II) complexes effective in vivo against murine tumors sensitive or resistant to cisplatin and tetraplatin. J Cancer Res Clin Oncol 120(10):571-7, 1994. e-Pub 1994. PMID: 7929527.
Siddik ZH, al-Baker S, Thai G, Khokhar AR. Antitumor activity of isomeric 1,2-diaminocyclohexane platinum(IV) complexes. J Cancer Res Clin Oncol 120(7):409-14, 1994. e-Pub 1994. PMID: 8188734.
Ohno S, Siddik ZH, Kido Y, Zwelling LA, Bull JM. Thermal enhancement of drug uptake and DNA adducts as a possible mechanism for the effect of sequencing hyperthermia on cisplatin-induced cytotoxicity in L1210 cells. Cancer Chemother Pharmacol 34(4):302-6, 1994. e-Pub 1994. PMID: 8033297.
Al-Baker S, Siddik ZH, Khokhar AR. Synthesis and characterization of new antitumor trans-R,R-, trans-S,S- and cis-1,2-diaminocyclohexane platinum(IV) complexes. . J Coord Chem 31:109-116, 1994. e-Pub 1994.
Kido Y, Khokhar AR, al-Baker S, Siddik ZH. Modulation of cytotoxicity and cellular pharmacology of 1,2-diaminocyclohexane platinum (IV) complexes mediated by axial and equatorial ligands. Cancer Res 53(19):4567-72, 1993. e-Pub 1993. PMID: 8402629.
Ohno S, Strebel FR, Stephens LC, Siddik ZH, Baba H, Makino M, Khokhar AR, Bull JM. Haematological toxicity of carboplatin and cisplatin combined with whole body hyperthermia in rats. Br J Cancer 68(3):469-74, 1993. e-Pub 1993. PMID: 8353037.
Khokhar AR, Deng Y, al-Baker S, Yoshida M, Siddik ZH. Synthesis and antitumor activity of ammine/amine platinum(II) and (IV) complexes. J Inorg Biochem 51(3):677-87, 1993. e-Pub 1993. PMID: 8409984.
Khokhar AR, Deng Y, Kido Y, Siddik ZH. Preparation, characterization, and antitumor activity of new ethylenediamine platinum(IV) complexes containing mixed carboxylate ligands. J Inorg Biochem 50(2):79-87, 1993. e-Pub 1993. PMID: 8487040.
Kido Y, Khokhar AR, Siddik ZH. Differential cytotoxicity, uptake and DNA binding of tetraplatin and analogous isomers in sensitive and resistant cancer cell lines. Anticancer Drugs 4(2):251-8, 1993. e-Pub 1993. PMID: 8490203.
Yang LY, Trujillo JM, Siciliano MJ, Kido Y, Siddik ZH, Su YZ. Distinct P-glycoprotein expression in two subclones simultaneously selected from a human colon carcinoma cell line by cis-diamminedichloroplatinum (II). Int J Cancer 53(3):478-85, 1993. e-Pub 1993. PMID: 8094074.
Curley SA, Stone DL, Fuhrman GM, Hohn DC, Siddik ZH, Newman RA. Increased doxorubicin levels in hepatic tumors with reduced systemic drug exposure achieved with complete hepatic venous isolation and extracorporeal chemofiltration. Cancer Chemother Pharmacol 33(3):251-7, 1993. e-Pub 1993. PMID: 8269607.
Wondergem J, Siddik ZH, Strebel FR, Bull JM. Effect of whole body hyperthermia on cis-diamminedichloroplatinum (II)-induced antitumour activity and tissue Pt-distribution: do anaesthetics influence the therapeutic ratio?. Eur J Cancer 29A(4):549-54, 1993. e-Pub 1993. PMID: 8435209.
Klostergaard J, Leroux E, Siddik ZH, Khodadadian M, Tomasovic SP. Enhanced sensitivity of human colon tumor cell lines in vitro in response to thermochemoimmunotherapy. Cancer Res 52(19):5271-7, 1992. e-Pub 1992. PMID: 1394131.
Kido Y, Khokhar AR, Siddik ZH. Pharmacokinetics of intravenously injected [3H]tetrachloro(D,L-trans)1,2-diaminocyclohexane platinum (IV) (tetraplatin) in mice. Drug Metab Dispos 20(5):673-8, 1992. e-Pub 1992. PMID: 1358571.
Ohno S, Strebel FR, Stephens LC, Siddik ZH, Makino M, Klostergaard J, Tomasovic SP, Khokhar AR, Bull JM. Increased therapeutic efficacy induced by tumor necrosis factor alpha combined with platinum complexes and whole-body hyperthermia in rats. Cancer Res 52(15):4096-101, 1992. e-Pub 1992. PMID: 1638521.
Khokhar AR, Xu Q, Newman RA, Kido Y, Siddik ZH. Synthesis, characterization, and antitumor activity of new chloroethylamine platinum complexes. J Inorg Biochem 45(3):211-9, 1992. e-Pub 1992. PMID: 1634893.
Vadiei K, Siddik ZH, Khokhar AR, al-Baker S, Sampedro F, Perez-Soler R. Pharmacokinetics of liposome-entrapped cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexane platinum(II) and cisplatin given i.v. and i.p. in the rat. Cancer Chemother Pharmacol 30(5):365-9, 1992. e-Pub 1992. PMID: 1505075.
Khokhar AR, Xu QY, Newman RA, Siddik ZH. Preparation, characterization, and antitumor activity of water-soluble aminoalkanol platinum(II) complexes. J Inorg Biochem 43(1):57-63, 1991. e-Pub 1991. PMID: 1940901.
Wondergem J, Stephens LC, Strebel FR, Baba H, Ohno S, Siddik ZH, Newman RA, Bull JM. Effect of adriamycin combined with whole body hyperthermia on tumor and normal tissues. Cancer Res 51(13):3559-67, 1991. e-Pub 1991. PMID: 2054792.
Baba H, Stephens LC, Strebel FR, Siddik ZH, Newman RA, Ohno S, Bull JM. Protective effect of ICRF-187 against normal tissue injury induced by adriamycin in combination with whole body hyperthermia. Cancer Res 51(13):3568-77, 1991. e-Pub 1991. PMID: 1905199.
Ohno S, Siddik ZH, Baba H, Stephens LC, Strebel FR, Wondergem J, Khokhar AR, Bull JM. Effect of carboplatin combined with whole body hyperthermia on normal tissue and tumor in rats. Cancer Res 51(11):2994-3000, 1991. e-Pub 1991. PMID: 2032236.
Garteiz D, Siddik ZH, Newman RA. In vitro and in vivo murine metabolism of spirogermanium. Drug Metab Dispos 19(1):44-7, 1991. e-Pub 1991. PMID: 1673420.
Khokhar AR, Xu QY, Siddik ZH. Synthesis, characterization, and antitumor activity of 1,2-bis(diphenylphosphino) ethane platinum(II) and palladium(II) complexes. J Inorg Biochem 39(2):117-23, 1990. e-Pub 1990. PMID: 2380705.
Newman RA, Siddik ZH, Travis EL, Followill D, Ayele W, Burditt T, Krakoff IH. Assessment of pulmonary and hematologic toxicities of liblomycin, a novel bleomycin analog. Invest New Drugs 8(1):33-41, 1990. e-Pub 1990. PMID: 1693138.
Ho BT, Tansey LW, Engineer MS, Newman RA, Siddik ZH, Field WS, Krakoff IH. Beta-adrenoceptor binding studies with LY195448 and metabolites. Res Commun Chem Pathol Pharmacol 67(1):143-6, 1990. e-Pub 1990. PMID: 2158135.
Graham RA, Siddik ZH, Hohn DC. Extracorporeal hemofiltration: a model for decreasing systemic drug exposure with intra-arterial chemotherapy. Cancer Chemother Pharmacol 26(3):210-4, 1990. e-Pub 1990. PMID: 2357769.
Baba H, Siddik ZH, Strebel FR, Jenkins GN, Bull JM. Increased therapeutic gain of combined cis-diamminedichloroplatinum (II) and whole body hyperthermia therapy by optimal heat/drug scheduling. Cancer Res 49(24 Pt 1):7041-4, 1989. e-Pub 1989. PMID: 2582445.
Calvert AH, Newell DR, Gumbrell LA, O'Reilly S, Burnell M, Boxall FE, Siddik ZH, Judson IR, Gore ME, Wiltshaw E. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 7(11):1748-56, 1989. e-Pub 1989. PMID: 2681557.
Wondergem J, Bulger RE, Siddik ZH, Leygraaf JW, Strebel FR, Alonso M, Travis EL, Bull JM. A comparison of thermal enhancement of cis-diamminedichloroplatinum (II) induced renal and intestinal toxicities by whole body hyperthermia in the rat. Int J Radiat Oncol Biol Phys 16(6):1551-6, 1989. e-Pub 1989. PMID: 2722594.
Newman RA, Osborn S, Siddik ZH. Determination of tellurium in biological fluids by means of electrothermal vaporization-inductively coupled plasma-mass spectrometry (ETV-ICP-MS). Clin Chim Acta 179(2):191-6, 1989. e-Pub 1989. PMID: 2920448.
Wondergem J, Strebel FR, Siddik ZH, Newman RA, Bull JM. The effects of anaesthetics on cisplatinum-induced toxicity at normal temperatures and during whole-body hyperthermia: the influence of NaCl concentration of the vehicle. Int J Hyperthermia 4(6):643-54, 1988. e-Pub 1988. PMID: 3171259.
Siddik ZH, Newman RA. Use of platinum as a modifier in the sensitive detection of tellurium in biological samples. Anal Biochem 172(1):190-6, 1988. e-Pub 1988. PMID: 3189763.
Bull JM, Strebel FR, Sunderland BA, Bulger RE, Edwards M, Siddik ZH, Newman RA. o-(beta-Hydroxyethyl)-rutoside-mediated protection of renal injury associated with cis-diamminedichloroplatinum(II)/hyperthermia treatment. Cancer Res 48(8):2239-44, 1988. e-Pub 1988. PMID: 3349489.
Lautersztain J, Perez-Soler R, Turpin J, Khokhar AR, Siddik ZH, Schmidt K, Lopez-Berestein G. Cellular pharmacology of liposomal cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexaneplatinum (II) in mouse resident peritoneal macrophages, Kupffer cells, and hepatocytes. Cancer Res 48(5):1300-6, 1988. e-Pub 1988. PMID: 3342409.
Siddik ZH, Jones M, Boxall FE, Harrap KR. Comparative distribution and excretion of carboplatin and cisplatin in mice. Cancer Chemother Pharmacol 21(1):19-24, 1988. e-Pub 1988. PMID: 3277732.
Khokhar AR, Wright K, Siddik ZH, Perez-Soler R. Organ distribution and tumor uptake of liposome entrapped cis-bis-neodecanoato trans-R, R-1,2 diaminocyclohexane platinum (II) administered intravenously and into the proper hepatic artery. Cancer Chemother Pharmacol 22(3):223-7, 1988. e-Pub 1988. PMID: 3409456.
Dible SE, Siddik ZH, Harrap KR. The comparative tissues distribution of platinum and 14C in mice receiving 14C-labelled carboplatin. Cancer Chemother Pharmacol 22(1):11-6, 1988. e-Pub 1988. PMID: 3293838.
Newell DR, Siddik ZH, Gumbrell LA, Boxall FE, Gore ME, Smith IE, Calvert AH. Plasma free platinum pharmacokinetics in patients treated with high dose carboplatin. Eur J Cancer Clin Oncol 23(9):1399-405, 1987. e-Pub 1987. PMID: 3315699.
Dible SE, Siddik ZH, Boxall FE, Harrap KR. The effect of diethyldithiocarbamate on the haematological toxicity and antitumour activity of carboplatin. Eur J Cancer Clin Oncol 23(6):813-8, 1987. e-Pub 1987. PMID: 2820745.
Siddik ZH, Newell DR, Boxall FE, Harrap KR. The comparative pharmacokinetics of carboplatin and cisplatin in mice and rats. Biochem Pharmacol 36(12):1925-32, 1987. e-Pub 1987. PMID: 3297068.
Siddik ZH, Boxall FE, Harrap KR. Flameless atomic absorption spectrophotometric determination of platinum in tissues solubilized in hyamine hydroxide. Anal Biochem 163(1):21-6, 1987. e-Pub 1987. PMID: 3039867.
Siddik ZH, Boxall FE, Harrap KR. Haematological toxicity of carboplatin in rats. Br J Cancer 55(4):375-9, 1987. e-Pub 1987. PMID: 3555590.
Gore ME, Hills CA, Siddik ZH, Sloane JP, Winkley AR, Smith IE, Millar JL. Priming reduces the bone marrow toxicity of carboplatin. Eur J Cancer Clin Oncol 23(1):75-80, 1987. e-Pub 1987. PMID: 3297714.
Siddik ZH. Minimising the organ toxic effects of chemotherapy. Eur J Cancer Clin Oncol 22(8):905-7, 1986. e-Pub 1986. PMID: 3770047.
Calvert AH, Alison DL, Harland SJ, Robinson BA, Jackman AL, Jones TR, Newell DR, Siddik ZH, Wiltshaw E, McElwain TJ, et al. A phase I evaluation of the quinazoline antifolate thymidylate synthase inhibitor, N10-propargyl-5,8-dideazafolic acid, CB3717. J Clin Oncol 4(8):1245-52, 1986. e-Pub 1986. PMID: 3734849.
Radacic M, Siddik ZH, Newell DR. Para-amino-hippurate (PAH) test as an indicator of nephrotoxicity. . Yugoslav Physiol Pharmacol Acta 21:277-278, 1986. e-Pub 1986.
Calvert AH, Harland SJ, Newell DR, Siddik ZH, Harrap KR. Phase I studies with carboplatin at the Royal Marsden Hospital. Cancer Treat Rev 12 Suppl A:51-7, 1985. e-Pub 1985. PMID: 3910222.
Millar BC, Siddik ZH, Millar JL, Jinks S. Mesna does not reduce cisplatin induced nephrotoxicity in the rat. Cancer Chemother Pharmacol 15(3):307-9, 1985. e-Pub 1985. PMID: 3931929.
Harland SJ, Newell DR, Siddik ZH, Chadwick R, Calvert AH, Harrap KR. Pharmacokinetics of cis-diammine-1,1-cyclobutane dicarboxylate platinum(II) in patients with normal and impaired renal function. Cancer Res 44(4):1693-7, 1984. e-Pub 1984. PMID: 6367971.
Trush MA, Mimnaugh EG, Siddik ZH, Gram TE. Bleomycin-metal interaction: ferrous iron-initiated chemiluminescence. Biochem Biophys Res Commun 112(2):378-83, 1983. e-Pub 1983. PMID: 6189484.
Litterst CL, Tong S, Hirokata Y, Siddik ZH. Stimulation of microsomal drug oxidation in liver and kidney of rats treated with the oncolytic agent cis-dichlorodiammineplatinum-II. Pharmacology 26(1):46-53, 1983. e-Pub 1983. PMID: 6681909.
Hirokata Y, Tong S, Siddik ZH, Trush MA, Mimnaugh EG, Gram TE. Sex-dependent differences in the effects of portacaval anastomosis on hepatic monooxygenases in rats. Biochem Pharmacol 31(4):499-502, 1982. e-Pub 1982. PMID: 6802138.
Litterst CL, Tong S, Hirokata Y, Siddik ZH. Alterations in hepatic and renal levels of glutathione and activities of glutathione S-transferase from rats treated with cis-dichlorodiammineplatinum-II. Cancer Chemother Pharmacol 8(1):67-71, 1982. e-Pub 1982. PMID: 7201357.
Calvert AH, Harland SJ, Newell DR, Siddik ZH, Jones AC, McElwain TJ, Raju S, Wiltshaw E, Smith IE, Baker JM, Peckham MJ, Harrap KR. Early clinical studies with cis-diammine-1,1-cyclobutane dicarboxylate platinum II. Cancer Chemother Pharmacol 9(3):140-7, 1982. e-Pub 1982. PMID: 6761010.
Drew R, Siddik Z. Drug uptake by lung slices from paraquat-pretreated rats. Experientia 37(10):1093-5, 1981. e-Pub 1981. PMID: 7308402.
Drew R, Siddik ZH, Mimnaugh EG, Gram TE. Species and dose differences in the accumulation of imipramine by mammalian lungs. Drug Metab Dispos 9(4):322-6, 1981. e-Pub 1981. PMID: 6114830.
Siddik ZH, Drew R, Gram TE. Metabolism and biliary excretion of sulfobromophthalein in vitamin A deficiency. Biochem Pharmacol 29(19):2583-8, 1980. e-Pub 1980. PMID: 7426064.
Siddik ZH, Mimnaugh EG, Trush MA, Gram TE. The effect of vitamin A deficiency on hepatic, renal and pulmonary glutathione S-transferase activities in the rat. Biochem J 188(3):889-93, 1980. e-Pub 1980. PMID: 7470042.
Sikic BI, Siddik ZH, Gram TE. Relative pulmonary toxicity and antitumor effects of two new bleomycin analogs, pepleomycin and tallysomycin A. Cancer Treat Rep 64(4-5):659-67, 1980. e-Pub 1980. PMID: 6159079.
Siddik ZH, Trush MA, Gram TE. Pulmonary accumulation of drugs in vitamin A deficiency. Lung 157(4):209-17, 1980. e-Pub 1980. PMID: 7401686.
Siddik ZH, Drew R, Litterst CL, Mimnaugh EG, Sikic BI, Gram TE. Hepatic cytochrome P-450-dependent metabolism and enzymatic conjugation of foreign compounds in vitamin A-deficient rats. Pharmacology 21(6):383-90, 1980. e-Pub 1980. PMID: 7220590.
Drew R, Siddik ZH. Effect of a specific 5HT uptake inhibitor (citalopram) on drug accumulation by rat lung slices. Pharmacology 20(1):27-31, 1980. e-Pub 1980. PMID: 6929555.
Siddik ZH, Barnes RD, Dring LG, Smith RL, Williams RT. The metabolism of lysergic acid DI[14C]ethylamide ([14C]LSD) in the isolated perfused rat liver. Biochem Pharmacol 28(20):3081-91, 1979. e-Pub 1979. PMID: 518707.
Siddik ZH, Barnes RD, Dring LG, Smith RL, Williams RT. The fate of lysergic acid DI[14C]ethylamide ([14C]LSD) in the rat, guinea pig and rhesus monkey and of [14C]iso-LSD in rat. Biochem Pharmacol 28(20):3093-101, 1979. e-Pub 1979. PMID: 117811.
Siddik ZH, Drew R, Gram TE. The effect of chlorpromazine on the uptake and efflux of paraquat in rat lung slices. Toxicol Appl Pharmacol 50(3):443-50, 1979. e-Pub 1979. PMID: 516057.
Drew R, Siddik ZH, Gram TE. Uptake and efflux of 14C-paraquat by rat lung slices: the effect of imipramine and other drugs. Toxicol Appl Pharmacol 49(3):473-8, 1979. e-Pub 1979. PMID: 473214.
Mimnaugh EG, Siddik ZH, Trush MA, Drew R, Gram TE. The effect of unilateral pneumonectomy on in vitro drug metabolism by the contralateral lung of rabbits. Drug Metab Dispos 7(4):208-10, 1979. e-Pub 1979. PMID: 39721.
Mimnaugh EG, Siddik ZH, Drew R, Sikic BI, Gram TE. The effects of alpha-tocopherol on the toxicity, disposition, and metabolism of adriamycin in mice. Toxicol Appl Pharmacol 49(1):119-26, 1979. e-Pub 1979. PMID: 473197.
Siddik ZH, Sikic BI, Drew R, Mimnaugh EG, Litterst CL, Gram TE. Lack of correlation between cortisol-induced precocious maturation of the fetal rabbit lung and drug metabolism. Biochem Pharmacol 28(5):683-5, 1979. e-Pub 1979. PMID: 444254.
Siddik ZH, Barnes RD, Dring LG, Smith RL, Williams RT. The fate of lysergic acid di[ 14C]ethlamide ([14-C]LSD) in the rat. Biochem Soc Trans 3(2):290-2, 1975. e-Pub 1975. PMID: 1132562.
Subramaniam B, Siddik ZH, Nagoor NH. Development and validation of a reversed-phase HPLC method for quantification of 1’-acetoxychavicol acetate content in a nanostructured lipid carrier formulation. Br J Pharm Sci,.

Invited Articles

Farooqi AA, Siddik ZH. Platelet-derived growth factor (PDGF) signalling in cancer: rapidly emerging signalling landscape. Cell Biochem Funct 33(5):257-65, 2015. e-Pub 2015. PMID: 26153649.
Siddik ZH. Agents targeting apoptosis take center stage in the battle against cancer. J. Rashid Latif Med Coll 2(1):7-9, 2013. e-Pub 2013.
Siddik ZH. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 22(47):7265-79, 2003. e-Pub 2003. PMID: 14576837.
Siddik ZH. Biochemical and molecular mechanisms of cisplatin resistance. Cancer Treat Res 112:263-84, 2002. e-Pub 2002. PMID: 12481720.
Pusztai L, Siddik ZH, Mills GB, Bast RC. Physiologic and pathologic drug resistance in ovarian carcinoma--a hypothesis based on a clonal progression model. Acta Oncol 37(7-8):629-40, 1998. e-Pub 1998. PMID: 10050979.
Newman RA, Siddik ZH. In situ localization and quantitation of anticancer drugs. The Cancer Bulletin 46:67- 71, 1994. e-Pub 1994.
Siddik ZH, Newman RA. Metabolism of new anticancer agents. Pharmacol Ther 41(1-2):163-94, 1989. e-Pub 1989. PMID: 2652150.

Review Articles

Farooqi AA, de la Roche M, Djamgoz MBA, Siddik ZH. Overview of the oncogenic signaling pathways in colorectal cancer: Mechanistic insights. Semin Cancer Biol 58:65-79, 2019. e-Pub 2019. PMID: 30633978.
Martinez-Rivera M, Siddik ZH. Resistance and gain-of-resistance phenotypes in cancers harboring wild-type p53. Biochem Pharmacol 83(8):1049-62, 2012. e-Pub 2012. PMID: 22227014.
Siddik ZH, Hagopian GS, Thai G, Tomisaki S, Toyomasu T, Khokhar AR. Role of p53 in the ability of 1,2-diaminocyclohexane-diacetato-dichloro-Pt(IV) to circumvent cisplatin resistance. J Inorg Biochem 77(1-2):65-70, 1999. e-Pub 1999. PMID: 10626356.
Siddik ZH, Edwards MJ, Boddie AW. Isolated limb perfusion with chemotherapeutic agents for melanoma: a reevaluation of drug dosimetry. Eur J Cancer Clin Oncol 25(10):1393-7, 1989. e-Pub 1989. PMID: 2687001.

Editorials

Siddik ZH, Tomasovic SP. Hot Topic Editorial Comment: Mammalian cells adapted to growth at pH 6.7 have elevated HSP27 levels and are resistant to cisplatin, by Wachsberger et al. Int. J. Hyperthermia 13:257-259, 1997.

Abstracts

Steino A, He G, Zhai B, Bacha JA, Brown DM, Daugagard M, Siddik ZH. VAL-083 (dianhydrogalactitol) synergizes with PARP inhibitors in BRCA-proficient and BRCA-deficient ovarian cancer models. AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics 20(12), 2021. e-Pub 2021.
He G, Thiabaud G, Shelton K, Segura L, Sessler JL, Finch R, Siddik ZH, Arambula JF. Preclinical tissue biodistribution and plasma pharmacokinetic studies with oxaliTEX, a novel platinum(IV)-based oxaliplatin prodrug. AACR Virtual Annual Meeting 2021 (#1073) 81(13), 2021. e-Pub 2021.
Sessler J L, Arambula J F, Thiabaud G, Siddik H Z. Preclinical Studies of OxaliTEX. International Symposium on Macrocyclic and Supramolecular Chemistry, 2020. e-Pub 2020.
Ozcan G, Leylek O, Ozcan G, He G, Siddik H Z. The role of p53 and drug uptake in cell density-dependent cisplatin resistance in ovarian cancer cells. Multidisciplinary Cancer Research and Basic Oncology Congress, 2018. e-Pub 2018.
SiddikZH. The perils and possibilities of p53-based personalized cancer therapy. International Santorini Conference on Systems Medicine and Personalized Health and Therapy, 2018. e-Pub 2018.
BachaJ, HeG, SteinoA, BrownD, SiddikZ. Dianhydrogalactitol (VAL-083) has a distinct mechanism of action that suggests combination with PARP inhibitors as an effective therapeutic strategy. AACR 2018 Annual Meeting, 2018. e-Pub 2018.
Steino A, He G, Zhai B, Bacha JA, Lu S, Brown DM, Daugagard M, Siddik ZH. Assessment of dianhydrogalactitol (VAL-083) in the treatment of relapsed or refractory non-small cell lung cancer. 17th World Conference on Lung Cancer, 2016. e-Pub 2016.
Steino A, He G, Zhai B, Bacha JA, Lu S, Brown DM, Daugagard M, Siddik ZH. Assessment of dianhydrogalactitol in the treatment of relapsed or refractory non-small cell lung cancer. AACR New Horizons in Cancer Research: Delivering Cures Through Cancer Science 2016, 2016. e-Pub 2016.
Steino A, Michelle-Martinez M, He G, Xie X, Bacha JA, Brown DM, Siddik ZH. Activity of dianhydrogalactitol (VAL-083) in ovarian tumor models, sensitive or resistant to cisplatin. AACR 11th Biennial Ovarian Cancer Research Symposium, 2016. e-Pub 2016.
Steino A, He G, Michelle-Martinez M, Bacha JA, Brown D, Siddik ZH. Enhanced in vitro activity of dianhydrogalactitol (VAL-083) in combination with platinum drugs: impact of p53 and platinum-resistance. AACR 107th Annual Meeting, 2016. e-Pub 2016.
Steino A, He G, Bacha JA, Kanekal S, Brown D, Siddik ZH. In vitro activity of dianhydrogalactitol alone or with platinum drugs in the treatment of non-small cell lung cancer. AACR 106th Annual Meeting 2015, Philadelphia, 2015. e-Pub 2015.
Steino A, He G, Bacha JA, Kanekal S, Brown DM, Siddik ZH. Activity of dianhydrogalactitol alone or with platinum drugs against non-small cell lung cancer cell lines. Clin Oncol, 2015. e-Pub 2015.
Bacha JA, Martinez-Rivera M, He G, Xie X, Steino A, Kanekal S, Brown DM, Siddik ZH. A comparison of the mechanisms and cytotoxic activity of dianhydrogalactitol (VAL-083) to cisplatin in ovarian tumor models harboring wild-type and mutant. AACR Advances in Ovarian Cancer, 2015. e-Pub 2015.
Huang Z, He G, Meraz IM, Khokhar AR, Siddik ZH. Gain-of-Resistance to cisplatin and its circumvention in ovarian tumor cells harboring wild type p53. Eur Soc Gyn Oncol-18th Int'l Mtg Liverpool UK, 2013. e-Pub 2013.
Steino A, Bacha JA, Garner WJ, Kanekal S, Siddik ZH, Brown DM. The unique mechanism of action of VAL-083 may provide a new treatment option for some chemo-resistant cancers. AACR-NCI-EORTC International Conference, Boston, 2013. e-Pub 2013.
Kim ES, Kilari D, Tang X, Chow CW, Fujimoto J, Kalhor N, Swisher S, Wistuba II, Stewart DJ, Siddik ZH. Copper transporter CTR1 expression and tissue platinum concentration in NSCLC. Lung Cancer 85(1):88-93, 2013. e-Pub 2013. PMID: 24792335.
Kim ES, He G, C-W C, Fujimoto J Kalhor N, Swisher SG, Wistuba II, Stewart DJ, Siddik ZH. Tissue platinum concentration and tumor response in non-small cell lunch cancer,. Texas Soc Clin Oncol, San Antonio TX, 2011. e-Pub 2011.
Kim ES, He G, C-W C, Fujimoto J, Kalhor N, Swisher SG, Wistuba II, Stewart DJ, Siddik ZH. Correlation between tissue platinum concentration and tumor response in non-small cell lung cancer. 14th World Conf. on Lung Cancer, Amsterdam, The Netherlands, 2011. e-Pub 2011.
He G, Kuang J, Kommen J, Kobayashi R, Khokhar AR, Siddik ZH. DNA damage by platinum-based drugs induces P21-dependent recruitment of PCNA as a homotrimer into the inhibited G-1 phase CDK complex. Proc. Am Assoc Cancer Res, 2011. e-Pub 2011.
Meraz IM, Khokhar A, Siddik ZH. Defective Check Point Kinase 2 (Chk2) Expression in Cisplatin-resistant Ovarian Tumor Cells Impedes wild-type P53 function. Proc. Am. Assoc. Cancer Res 51, 2010. e-Pub 2010.
He G, Kuang J, Khokhar AR, Siddik ZH. The underlying basis for divergent cell cycles kinetics following checkpoint activation by cisplatin and a platinum (IV) analog. Am Assoc Cancer Res 51, 2010. e-Pub 2010.
He G, Kuang J, Khokhar AR, Siddik ZH. The paradox in cell cycle effects of cisplatin; failure of tumor cells to accumulate in G1 following activation of G1-checkpoint proc. 13th World Congress on Advances in Oncology and 11th Int'l symposium on Molecular Medicine, 2010. e-Pub 2010.
Huang Z, He G, Khokhar A, Siddik ZH. Paradoxical molecular changes in cisplatin-resistant ovarian tumor cells: up-regulation of drug-sensitizing and down-regulation of resistance-inducing genes. Proc Am Assoc Cancer Res 50, 2009. e-Pub 2009.
Huang Z, He G, Khokhar AR, Siddik ZH. Molecular profiling of an isogenic sensitive-resistant pair of ovarian tumor cell lines identifies hepatocyte growth factor as downregulated in cisplatin resistance. Proc Am Assoc Cancer Res, 2008. e-Pub 2008.
Siddik ZH. A rational microarray approach to investigate the paradox of wild-type p53 in refractory cancers. Proc. 13th World Congress on Advances in Oncology and 11th Int’l Symposium on Molecular Medicine, 2008. e-Pub 2008.
Lu Y, Li X, Liang K, Luwor R, Siddik ZH, Mills GB, Mendelsohn J, Fan Z. Epidermal growth factor receptor (EGFR) ubiquitination as a mechanism of acquired resistance to the anti-EGFR monoclonal antibody cetuximab. Proc Am Assoc Cancer Res (98th Annu. Mtg. Amer. Assoc. Cancer Res., April 14-18, Los Angeles, California) 48, 2007. e-Pub 2007.
Kurokawa T, Siddik ZH. Effect of casein kinase 2 (ck2) inhibitors on antitumor activity of cisplatin in an isogenic pair of sensitive and resistant ovarian tumor cell lines. Proc Am Assoc Cancer Res 48, 2007. e-Pub 2007.
Strebel FR, Siddik ZH, Deng W, Rowe RW, Bull JMC. Long-duration, fever-range, thermal therapy increases oxaliplatin-induced cell-kill, cellular platinum uptake, and formation of platinum-DNA adducts in breast cancer cells. Proc World Conference on Interventional Oncology and Society for Thermal Medicine, 2007. e-Pub 2007.
Tavana B, Huang ZF, Khokhar A, Bornmann WG, Siddik ZH. Downregulation of p21 induces cisplatin resistance in tumor cells harboring wild-type p53. Proc Am Assoc Cancer Res 48, 2007. e-Pub 2007.
Siddik ZH, He G, Watanabe M, Mujoo K, Khokhar AR, Kuang J. Circumvention of drug resistance in human tumors harboring wild-type p53. Proc Am Assn Cancer Res 47, 2006. e-Pub 2006.
Song I, Savaraj N, Siddik ZH, Liu P, Wei Y, Wu CJ, Kuo MT. Role of human copper transporter Ctr1 in the transport of platinum-based antitumor agents in cisplatin-sensitive and cisplatin-resistant cells. Proc Am Assn Cancer Res 46:Abs 1483, 2005. e-Pub 2005.
Siddik ZH, He G, Koomen J, Kobayashi R, Z-F H, Khokhar AR, Kuang J. p27 changes its binding to the Cdk4 and Cdk2 complexes during DAP-induced G1-phase checkpoint response. Proc Am Assn Cancer Res 46:Abs 2273, 2005. e-Pub 2005.
Siddik ZH, He G, Koomen J, Kobayashi R, Z-F H, Khokhar AR, Kuang J. Molecular and proteomic analysis of Cdk4 and Cdk2 complexes following G1-phase checkpoint response to DNA damage. Proc Am Assn Cancer Res 45:Abs 2333, 2004. e-Pub 2004.
Sumiyoshi Y, Ojima H, Mujoo K, Khokhar AR, Siddik ZH. Significance of mismatch repair in cisplatin resistance and induction of cross-resistance to diverse DNA-damaging antitumor drugs. International Platinum Symposium, New York, 2003. e-Pub 2003.
Sumiyoshi Y, Ojima H, Mujoo K, Khokhar AR, Siddik ZH. Cross-resistance patterns of DNA-interactive agents in cisplatin-resistant ovarian cancer. Proc Am Assn Cancer Res 44, 2003. e-Pub 2003.
Sumiyoshi Y, Ojima H, Mujoo K, Kondo Y, L-L S, J-PJ I, Ghosh S, Farquhar D, Khokhar AR, Siddik ZH. Influence of p53 on the role of mismatch repair in cisplatin resistance and cross-resistance to other antitumor agents. AACR-NCI-EORTC International Conference, Boston, 2003. e-Pub 2003.
Siddik ZH, He G, Koomen J, Kobayashi R, Z-F H, Khokhar AR, Kuang J. Biochemical and proteomic characterization of Cdk4 and Cdk2 complexes formed in response to G1-phase checkpoint activation by a platinum-based drug. International Platinum Symposium, New York, 2003. e-Pub 2003.
Watanabe M, Mujoo K, Khokhar AR, Siddik ZH. Circumventing mechanisms of drug resistance in breast tumor cells overexpressing HER2/neu. Department of Defense Era of Hope Conference, Orlando, FL, 2002. e-Pub 2002.
He G, Siddik ZH, Huang Z, Wu W, Pan S, Khokhar AR, Kuang J. Mechanism of inhibition of Cdk4 and Cdk2 activities in the G1 phase checkpoint response induced by the DNA-damaging agent DACH-acetato-Pt. Proc Am Assn Cancer Res 43:797, 2002. e-Pub 2002.
Kuang J, He G, Huang Z, Khokhar AR, Siddik ZH. Differential effects of cisplatin and its analog DACH-acetato-Pt on the p53-p21 signaling pathway. Proc Am Assn Cancer Res 43:795, 2002. e-Pub 2002.
Ojima H, Watanabe M, Mujoo K, Hennessey P, Khokhar AR, Siddik ZH. Oxaliplatin resistant human ovarian tumor cells have low cross-resistance to the platinum analog DACH-Ac-Pt. Proc Am Assn Cancer Res 43:424, 2002. e-Pub 2002.
Mujoo K, Watanabe M, Hennessey P, Khokhar AR, Siddik Z H. Cytotoxicity of the platinum complex DACH-AC-Pt against refractory human prostate cancer cells. Proc Am Assn Cancer Res 43:260-261, 2002. e-Pub 2002.

Book Chapters

Siddik ZH. Alkylating Agents and Platinum Antitumor Compounds. In: In: Holland-Frei Cancer Medicine. 9th, Ch. 58, pp 649-664, 2017.
Siddik ZH. Apoptosis in cancer: mechanisms, deregulation, and therapeutic targeting. In: Cancer Drug Design and Discovery. 2nd, 357-390, 2014.
Siddik ZH. Targeting p21-dependent pathways for cell death in cancer therapy. In: Checkpoint Controls and Targets in Cancer Therapy. Humana Press, 199-213, 2010.
Siddik ZH. Drug resistance and the tumor suppressor p53: The paradox of wild-type genotype in chemorefractory cancers. In: Drug Resistance in Cancer Cells. Humana Press, 209-231, 2009.
Siddik ZH. Cisplatin resistance: Molecular basis of a multifaceted impediment. In: Cancer Drug Discovery and Development: Cancer Drug Resistance. Humana Press, pp. 283-307, 2006.
Siddik ZH. Mechanism of action of cancer chemotherapeutic agents: DNA-interactive alkylating agents and antitumor platinum-based drugs. In: The Cancer Handbook. Macmillan Publishers, pp. 1295-1311, 2002.
Siddik ZH. Biochemical and molecular mechanisms of cisplatin resistance. In: Clinically Relevant Drug Resistance to Anticancer Agents. Kluwer Academic Publishers, Inc, pp. 263-284, 2002.
Prasad SY, Khokhar AR, Siddik ZH. Potentiation by L-buthionine sulfoximine (BSO) of cytotoxicity of platinum(IV) complexes in sensitive and resistant human ovarian carcinoma cells. In: Metal Ions in Biology and Medicine. John Libbey, pp. 365-370, 1994.
Siddik ZH, Newman RA. Metabolism of new anticancer agents. In: International Encyclopedia of Pharmacology and Therapeutics - Anticancer Drugs: Antimetabolite Metabolism and Natural Anticancer Agents. Pergamon Press, pp. 437-480, 1994.
Perez-Soler R, Siddik ZH, Vadiei K, Krakoff IH, Khokhar AR. Pharmacological studies with new liposome- entrapped cisplatin derivatives. In: Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy. Plenum Press, pp. 377-389, 1991.
Siddik ZH, Newell DR. Radiochemicals in cancer research and clinical oncology. In: Critical Reports on Applied Chemistry: Biomedical Research Using Radiochemicals - Current and Future Trends. John Wiley & Sons Ltd, pp. 118- 150, 1988.
Harrap KR, Jones M, Goddard PM, Orr RM, Siddik ZH. Drug resistance as a focus for new drug design. In: Mechanisms of Drug Resistance in Neoplastic Cells. Academic Press, pp. 307-328, 1988.
Siddik ZH, Boxall FE, Harrap KR. Tissue solubilization in hyamine hydroxide for the flameless atomic absorption spectrophotometric determination of platinum. In: Biochemical Mechanisms of Platinum Antitumour Drugs. IRL Press, pp. 361-366, 1986.
Siddik ZH, Dible SE, Boxall FE, Harrap KR. Renal pharmacokinetics and toxicity of cisplatin and carboplatin in animals. In: Biochemical Mechanisms of Platinum Antitumour Drugs. IRL Press, pp. 171-198, 1986.
Newell DR, Siddik ZH, Harrap KR. HPLC analysis of cisplatin analogues in biological fluids. In: Methodological Surveys in Biochemistry and Analysis: Drug Determinations in Therapeutic and Forensic Contexts. Plenum, pp. 145-153, 1984.
Siddik ZH, Newell DR, Boxall FE, Jones M, McGhee KG, Harrap KR. Biliary excretion, renal handling, and red cell uptake of cisplatin and CBDCA in animals. In: Platinum Coordination Complexes in Cancer Chemotherapy. Martinus Nijhoff, pp. 90-102, 1984.
Siddik ZH, Trush MA, Gram TE. Absorption and distribution of drugs. In: Modern Pharmacology. Little Brown and Co, pp. 20-36, 1982.
Siddik ZH, Mimnaugh EG, Trush MA, Gram TE. Hepatic and extrahepatic glutathione S-transferase activities in Vitamin A deficiency. In: Microsomes, Drug Oxidations and Chemical Carcinogenesis. Academic Press, pp. 679-682, 1980.
Gram TE, Sikic BI, Litterst CL, Mimnaugh EG, Drew R, Siddik ZH. The role of the lung in the metabolism and disposition of xenobiotics. In: Industrial and Environmental Xenobiotics, pp. 53-58,, 1978.
Siddik ZH. Alkylating Agents and Platinum Antitumor Compounds. In: In: Holland-Frei Cancer Medicine. 10th.

Books (edited and written)

Boonstra J, Bunz F, Kuang J, Kramer A, Xiong Y, Lee MH, Nakanishi M, Alao JP, Lozano G, Giordano A, Friedenson B, Kaina B, Pevarello P, Eastman A, Siddik ZH, Bast R, Zhang H, Taylor SS, Rudolph J. Checkpoint Controls and Targets in Cancer Therapy. Humana Press, 2010.
Bates S, Fidler IJ, Kondo Y, Reddy EP, Mehta K, Hodkinson PS, Huang P, Aggarwal BB, Siddik ZH, Ali-Osman F, Ozoplat B, Calin G, Troester M, Price P, Chan MM. Drug Resistance in Cancer Cells. Humana Press, 2009.

Patents

Siddik ZH, Khokhar AR. Platinum complexes as antitumor agents in combination with biochemical modulation. Filed Sept 2002. Patent Number: U.S. Provisional Patent Application Serial No. 60/409,813.
Khokhar AR, Siddik ZH, Al-Baker S. Diamine platinum(IV) complexes having mixed carboxylate ligands as antitumor agents. Patent Number: U.S. Patent No. 5,288,887.
Khokhar AR, Siddik ZH, Newman RA. WATER SOLUBLE 1,2-DIAMINOCYCLOHEXANE PLATINUM (IV) COMPLEXES AS ANTITUMOR AGENTS. Patent Number: International Application No. PCT/US1989/004644.
Khokhar AR, Siddik ZH. Diamine platinum complexes as antitumor agents. Patent Number: U.S. Patent No. 5,434,256.
Siddik ZH, Khokhar AR. Platinum complexes as antitumor agents in combination with biochemical modulation. Patent Number: International Application No.: PCT/US2003/027860.
Sessler JL, Arambula J, Siddik ZH, Thiabaud G. Texaphyrin-PT(IV) Conjugates and Compositions for Use in Overcoming Platinum Resistance. Patent Number: PCT/US2015/035229.
Khokhar AR, Siddik ZH. Diamine platinum complexes as antitumor agents. Patent Number: U.S. Patent No. 5,393,909.
Sessler JL, Arambula J, Siddik ZH, Thiabaud G. Texaphyrin-PT(IV) Conjugates and Compositions for Use in Overcoming Platinum Resistance. Patent Number: 10,406,167.
Sessler JL, Arambula J, Siddik ZH, Thiabaud G. Texaphyrin-PT(IV) Conjugates and Compositions for Use in Overcoming Platinum Resistance. Patent Number: , EPA15806650.6.
Siddik ZH, Khokhar AR. Platinum complexes as antitumor agents in combination with biochemical modulation. Patent Number: United States Patent Application No. 20040097423.
Khokhar AR, Siddik ZH, Newman RA. Water soluble 1,2-diaminocyclohexane platinum (IV) complexes as antitumor agents. Patent Number: U.S. Patent No. 5,318,962.

Less

CV information above last modified July 22, 2026

Zahid Hussain Siddik, Ph.D.

Present Title & Affiliation

Primary Appointment

Dual/Joint/Adjunct Appointment

Research Interests

Education & Training

Degree-Granting Education

Postgraduate Training

Experience & Service

Faculty Academic Appointments

Administrative Appointments/Responsibilities

Other Professional Positions

Extramural Institutional Committee Activities

Editorial Activities

Honors & Awards

Professional Memberships

Selected Presentations & Talks

Local Presentations

National Presentations

International Presentations

Formal Peers

Grant & Contract Support

Selected Publications

Peer-Reviewed Articles

Invited Articles

Review Articles

Other Articles

Editorials

Abstracts

Book Chapters

Books (edited and written)

Patents

Patient Reviews

Related Links

Care Centers and Clinics

Departments and Divisions

Labs

Help #EndCancer

Zahid Hussain Siddik, Ph.D.

Present Title & Affiliation

Primary Appointment

Dual/Joint/Adjunct Appointment

Research Interests

Education & Training

Degree-Granting Education

Postgraduate Training

Experience & Service

Faculty Academic Appointments

Administrative Appointments/Responsibilities

Other Professional Positions

Extramural Institutional Committee Activities

Editorial Activities

Honors & Awards

Professional Memberships

Selected Presentations & Talks

Local Presentations

National Presentations

International Presentations

Formal Peers

Grant & Contract Support

Selected Publications

Peer-Reviewed Articles

Invited Articles

Review Articles

Other Articles

Editorials

Abstracts

Book Chapters

Books (edited and written)

Patents

Patient Reviews

Request an Appointment

Related Links

Care Centers and Clinics

Departments and Divisions

Labs

Clinical Trials

Help #EndCancer

Give Now

Donate Blood

Shop UT MD Anderson